

Canadian atrial fibrillation anticoagulation (CAFA) study

Journal of the American College of Cardiology

18, 349-355

DOI: [10.1016/0735-1097\(91\)90585-w](https://doi.org/10.1016/0735-1097(91)90585-w)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Recent advances in cardiology.. Postgraduate Medical Journal, 1982, 58, 459-466.	0.9	1
2	How Should Results from Completed Studies Influence Ongoing Clinical Trials?. Annals of Internal Medicine, 1991, 115, 818-822.	2.0	20
3	Stroke Prevention in Nonvalvular Atrial Fibrillation. Annals of Internal Medicine, 1991, 115, 727-736.	2.0	59
4	Oral Anticoagulants. Chest, 1992, 102, 312S-326S.	0.4	12
5	Hemorrhagic Complications of Anticoagulant Treatment. Chest, 1992, 102, 352S-363S.	0.4	115
6	Antithrombotic Therapy for Venous Thromboembolic Disease. Chest, 1992, 102, 408S-425S.	0.4	68
7	Antithrombotic Therapy in Valvular Heart Disease. Chest, 1992, 102, 434S-444S.	0.4	27
8	Randomized Trials of Warfarin for Atrial Fibrillation. New England Journal of Medicine, 1992, 327, 1451-1453.	13.9	45
9	Non-rheumatic atrial fibrillation: warfarin or aspirin for all?. Heart, 1992, 68, 544-547.	1.2	7
10	Oral anticoagulant therapy. Urgent need for standardization.. Circulation, 1992, 86, 1332-1335.	1.6	18
11	Treatment of Chronic Nonvalvular Atrial Fibrillation in the Elderly. Medical Decision Making, 1992, 12, 239-249.	1.2	67
12	Management of Atrial Fibrillation. New England Journal of Medicine, 1992, 326, 1264-1271.	13.9	271
13	Antithrombotic Therapy in Atrial Fibrillation. Chest, 1992, 102, 426S-433S.	0.4	167
14	Stroke Prevention Trials in Atrial Fibrillation. Cerebrovascular Diseases, 1992, 2, 14-17.	0.8	0
15	Predictors of Thromboembolism in Atrial Fibrillation: II. Echocardiographic Features of Patients at Risk. Annals of Internal Medicine, 1992, 116, 6-12.	2.0	532
16	Antithrombotic treatment and atrial fibrillation.. BMJ: British Medical Journal, 1992, 305, 1445-1446.	2.4	43
17	Cost-Effective Intervention in Stroke. Pharmacoeconomics, 1992, 2, 468-499.	1.7	23
18	Cardiogenic embolism to the brain. Lancet, The, 1992, 339, 589-594.	6.3	170

#	ARTICLE	IF	CITATIONS
19	Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation. <i>New England Journal of Medicine</i> , 1992, 327, 1406-1412.	13.9	1,252
20	Thromboembolism in nonvalvular atrial fibrillation: the answer may be in the ventricle. <i>International Journal of Cardiology</i> , 1992, 37, 277-282.	0.8	10
21	The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF study. <i>American Heart Journal</i> , 1992, 124, 1567-1573.	1.2	73
22	Risk factors for systemic embolism in patients with paroxysmal atrial fibrillation. <i>American Heart Journal</i> , 1992, 124, 149-153.	1.2	56
24	Predictors of Thromboembolism in Atrial Fibrillation: I. Clinical Features of Patients at Risk. <i>Annals of Internal Medicine</i> , 1992, 116, 1-5.	2.0	459
25	Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective.. <i>BMJ: British Medical Journal</i> , 1992, 305, 1457-1460.	2.4	121
26	Warfarin Compared to Aspirin for Prevention of Arterial Thromboembolism in Atrial Fibrillation. <i>Cerebrovascular Diseases</i> , 1992, 2, 332-341.	0.8	11
27	Atrial Fibrillation: Epidemiology and the Risk and Prevention of Stroke. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992, 15, 1332-1346.	0.5	23
28	Current therapy for supraventricular tachycardia. <i>Current Problems in Cardiology</i> , 1992, 17, 414-477.	1.1	10
29	Left atrial thrombi in non-rheumatic atrial fibrillation: assessment of prevalence by transesophageal echocardiography. <i>International Journal of Cardiovascular Imaging</i> , 1993, 9, 65-72.	0.2	28
30	Update on warfarin: Special considerations for the elderly. <i>Geriatric Nursing</i> , 1993, 14, 167-168.	0.9	2
31	Atrial fibrillation: New management strategies. <i>Current Problems in Cardiology</i> , 1993, 18, 237-300.	1.1	10
32	Left atrial appendage flow velocity assessment using transesophageal echocardiography in nonrheumatic atrial fibrillation and systemic embolism. <i>American Journal of Cardiology</i> , 1993, 71, 192-196.	0.7	108
33	Low-dose amiodarone for atrial fibrillation. <i>American Journal of Cardiology</i> , 1993, 72, F75-F81.	0.7	63
34	Lone atrial fibrillation and anticoagulant therapy. <i>Clinical Cardiology</i> , 1993, 16, 504-506.	0.7	5
35	Stroke and atrial fibrillation: To anticoagulate or not. <i>Clinical Cardiology</i> , 1993, 16, 529-530.	0.7	1
36	Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. <i>American Journal of Medicine</i> , 1993, 95, 315-328.	0.6	821
37	Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study. <i>Annals of Internal Medicine</i> , 1993, 118, 511.	2.0	609

#	ARTICLE	IF	CITATIONS
38	Adverse Effects of Coumarin Anticoagulants. <i>Drug Safety</i> , 1993, 9, 263-271.	1.4	18
39	Prophylaxis and Treatment of Stroke. <i>Drugs</i> , 1993, 45, 329-337.	4.9	18
40	Overview of the randomized trials to prevent stroke in atrial fibrillation. <i>Annals of Epidemiology</i> , 1993, 3, 563-567.	0.9	26
41	Atrial fibrillation: Current understandings and research imperatives. <i>Journal of the American College of Cardiology</i> , 1993, 22, 1830-1834.	1.2	122
42	CARDIOVASCULAR DISEASE. <i>Lancet, The</i> , 1993, 341, 1376-1377.	6.3	10
43	Atrial fibrillation and anticoagulation: from randomised trials to practice. <i>Lancet, The</i> , 1993, 341, 1381-1384.	6.3	39
44	Anticoagulants for atrial fibrillation. <i>Lancet, The</i> , 1993, 342, 1251-1252.	6.3	11
45	Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. <i>Lancet, The</i> , 1993, 342, 1255-1262.	6.3	1,707
46	Warfarin: is it time to reduce target ranges again?. <i>Australian and New Zealand Journal of Medicine</i> , 1993, 23, 692-696.	0.5	4
47	Cardiogenic Thromboembolism: Review of Clinical Trials. <i>Platelets</i> , 1993, 4, 9-11.	1.1	0
48	Treatment of atrial fibrillation: Recommendations from a workshop arranged by the Medical Products Agency (Uppsala, Sweden) and the Swedish Society of Cardiology. <i>European Heart Journal</i> , 1993, 14, 1427-1433.	1.0	15
49	Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation. <i>New England Journal of Medicine</i> , 1993, 328, 1041-1043.	13.9	1
50	Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.. <i>Circulation</i> , 1993, 87, 659-675.	1.6	224
51	Anticoagulation in patients with atrial fibrillation. Not safe and not cheap.. <i>BMJ: British Medical Journal</i> , 1993, 307, 1492-1492.	2.4	6
52	Stroke Prophylaxis: Hypertension Management and Antithrombotic Therapy. <i>Annals of Pharmacotherapy</i> , 1993, 27, 471-479.	0.9	6
53	The use of expected value as an aid to decisions regarding anticoagulation in patients with atrial fibrillation.. <i>Stroke</i> , 1993, 24, 2128-2134.	1.0	8
54	Use of Ultrahigh Frequency Ventilation in Patients With ARDS. <i>Chest</i> , 1993, 103, 1413-1420.	0.4	44
55	Antithrombotic Therapy in Atrial Fibrillation-To the Editor. <i>Chest</i> , 1993, 104, 1939-1940.	0.4	0

#	ARTICLE	IF	CITATIONS
56	Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin.. Stroke, 1993, 24, 1458-1461.	1.0	52
57	Anticoagulation in patients with atrial fibrillation. Underuse of warfarin is multifactorial.. BMJ: British Medical Journal, 1993, 307, 1492-1493.	2.4	6
58	Heart disease in patients with stroke: Incidence, impact, and implications for rehabilitation part 1: Classification and prevalence. Archives of Physical Medicine and Rehabilitation, 1993, 74, 752-760.	0.5	152
59	Cardiac Arrhythmias: Syncope and Stroke. Neurologic Clinics, 1993, 11, 375-390.	0.8	10
60	Initial experience with the maze procedure for atrial fibrillation. Journal of Thoracic and Cardiovascular Surgery, 1993, 105, 1077-1087.	0.4	76
61	Preventing Systemic Embolism in Patients with Abnormal Ventricular Function. Cardiology Clinics, 1994, 12, 477-485.	0.9	1
62	Managing Chronic Atrial Fibrillation: A Markov Decision Analysis Comparing Warfarin, Quinidine, and Low-Dose Amiodarone. Annals of Internal Medicine, 1994, 120, 449.	2.0	77
63	Antithrombotic Therapy Prescribed for Patients with Non-Rheumatic Atrial Fibrillation. Scottish Medical Journal, 1994, 39, 110-111.	0.7	13
64	Preventing Systemic Embolization in Patients with Atrial Fibrillation. Cardiology Clinics, 1994, 12, 495-504.	0.9	4
65	Cardiac arrhythmias in elderly patients. Reviews in Clinical Gerontology, 1994, 4, 107-112.	0.5	0
66	Atrial Fibrillation and Stroke. Archives of Internal Medicine, 1994, 154, 1443.	4.3	138
67	Anticoagulation in Atrial Fibrillation. Archives of Internal Medicine, 1994, 154, 1945.	4.3	180
68	Cerebrovascular disease: a clinical approach. Reviews in Clinical Gerontology, 1994, 4, 289-310.	0.5	0
69	Recent advances in cardiology.. Postgraduate Medical Journal, 1994, 70, 257-274.	0.9	0
70	Warfarin or aspirin for non-rheumatic atrial fibrillation?. Drug and Therapeutics Bulletin, 1994, 32, 57-60.	0.3	3
71	Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association.. Circulation, 1994, 89, 1469-1480.	1.6	197
72	Patient preferences for stroke outcomes.. Stroke, 1994, 25, 1721-1725.	1.0	181
73	Bleeding complications to long-term oral anticoagulant therapy. Journal of Thrombosis and Thrombolysis, 1994, 1, 17-25.	1.0	27

#	ARTICLE	IF	CITATIONS
74	Spontaneous echo contrast on transthoracic echocardiography and left atrial thrombus in rheumatic mitral valve disease patients: A clinicopathologic study. <i>Clinical Cardiology</i> , 1994, 17, 547-551.	0.7	8
75	Non-anticoagulation in atrial fibrillation. <i>Irish Journal of Medical Science</i> , 1994, 163, 448-450.	0.8	6
76	A computerized intervention to improve timing of outpatient follow-up. <i>Journal of General Internal Medicine</i> , 1994, 9, 131-139.	1.3	57
77	Anticoagulation and Hemostasis in Cardiac Surgical Patients. <i>Journal of Cardiac Surgery</i> , 1994, 9, 443-461.	0.3	4
78	Incidence and Risks Associated with Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 1005-1010.	0.5	18
79	Anticoagulants: When and How?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 1011-1015.	0.5	3
80	Initial Experience with Intracardiac Atrial Defibrillation in Patients with Chronic Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 1067-1078.	0.5	114
81	Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 1994, 24, 755-762.	1.2	346
82	Left atrial appendage blood velocity and thromboembolic risk in patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 1994, 24, 1429-1430.	1.2	28
83	Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. <i>Journal of the American College of Cardiology</i> , 1994, 23, 961-969.	1.2	670
84	Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: Identification of a subgroup of patients at increased embolic risk. <i>Journal of the American College of Cardiology</i> , 1994, 23, 599-607.	1.2	321
85	Atrial fibrillation, stroke, and antithrombotic treatment. <i>American Heart Journal</i> , 1994, 127, 961-968.	1.2	18
86	Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. <i>Lancet, The</i> , 1994, 343, 886-889.	6.3	493
87	Aspirin and prevention of stroke. <i>Lancet, The</i> , 1994, 343, 233-235.	6.3	7
88	Aspirin or warfarin for non-rheumatic atrial fibrillation?. <i>Lancet, The</i> , 1994, 343, 683-684.	6.3	15
89	Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study*1. <i>Lancet, The</i> , 1994, 343, .	6.3	184
90	Stroke Prevention in Atrial Fibrillation II Study. <i>Lancet, The</i> , 1994, 343, 1508-1509.	6.3	6
91	Paroxysmal atrial fibrillation in pregnancy. <i>Current Obstetrics &amp; Gynaecology</i> , 1994, 4, 170-171.	0.2	0

#	ARTICLE	IF	CITATIONS
92	Optimal Management of Older Patients with Atrial Fibrillation. <i>Drugs and Aging</i> , 1994, 4, 184-193.	1.3	12
93	The Treatment of Atrial Fibrillation. <i>Drugs</i> , 1994, 48, 345-371.	4.9	83
94	Risk Factors Associated with Ischaemic Stroke. <i>CNS Drugs</i> , 1994, 1, 132-145.	2.7	2
95	Warfarin or Aspirin as Secondary Prevention of Ischaemic Stroke?. <i>CNS Drugs</i> , 1994, 2, 341-346.	2.7	0
96	Stroke prevention and AF. <i>Drugs and Therapy Perspectives</i> , 1994, 4, 11-13.	0.3	1
97	Transthoracic echo/Doppler in the identification of patients with chronic non-valvular atrial fibrillation at risk for thromboembolic events. <i>European Heart Journal</i> , 1994, 15, 1545-1551.	1.0	25
98	Interactions of Warfarin with Drugs and Food. <i>Annals of Internal Medicine</i> , 1994, 121, 676.	2.0	457
99	Medical Treatment for Stroke Prevention. <i>Annals of Internal Medicine</i> , 1994, 121, 41.	2.0	91
100	Comparison of a Standard and a Sensitive Thromboplastin in Monitoring Low Intensity Oral Anticoagulant Therapy. <i>American Journal of Clinical Pathology</i> , 1994, 102, 134-137.	0.4	3
101	Anticoagulant and Antiplatelet Therapy in Cardioembolic Stroke. <i>Cerebrovascular Diseases</i> , 1994, 4, 29-33.	0.8	2
102	Drug and Surgical Issues in Stroke Prevention. <i>Cerebrovascular Diseases</i> , 1994, 4, 16-25.	0.8	1
103	Stroke: the way things really are.. <i>Stroke</i> , 1994, 25, 1290-1294.	1.0	8
104	Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. , 1995, , CD000185.		4
105	Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. , 1995, , CD000186.		3
107	Antithrombotic Therapy in Atrial Fibrillation. <i>Chest</i> , 1995, 108, 352S-359S.	0.4	210
108	Hemorrhagic Complications of Anticoagulant Treatment. <i>Chest</i> , 1995, 108, 276S-290S.	0.4	145
109	Antithrombotic Therapy in Valvular Heart Disease. <i>Chest</i> , 1995, 108, 360S-370S.	0.4	21
110	Making Decisions About Antithrombotic Therapy in Heart Disease. <i>Chest</i> , 1995, 108, 457S-470S.	0.4	25

#	ARTICLE	IF	CITATIONS
111	Research in the Danish health service system: completeness and validity of prescription data, illustrated by analysis of utilization of oral anticoagulants. <i>International Journal of Risk and Safety in Medicine</i> , 1995, 7, 33-41.	0.3	14
112	Randomized comparison of aspirin and phenprocoumon for prevention of right-sided thromboembolic complications associated with transvenous defibrillation leads. <i>European Heart Journal</i> , 1995, 16, 986-992.	1.0	8
113	Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. <i>The Cochrane Library</i> , 2008, 2008, .	1.5	0
114	Contemporary management of atrial fibrillation. <i>Medical Clinics of North America</i> , 1995, 79, 1135-1152.	1.1	8
115	Cost-effectiveness analysis in heart disease, part II: Preventive therapies. <i>Progress in Cardiovascular Diseases</i> , 1995, 37, 243-271.	1.6	65
116	Quantification of blood echogenicity: Evaluation of a semiquantitative method of grading spontaneous echo contrast. <i>Ultrasound in Medicine and Biology</i> , 1995, 21, 1191-1198.	0.7	52
117	Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulant Therapy Study (AFASAK 2): Methods and design. <i>Journal of Thrombosis and Thrombolysis</i> , 1995, 2, 125-130.	1.0	7
118	Nonpharmacologic Approaches to the Treatment of Atrial Fibrillation and Atrial Flutter. <i>Journal of Cardiovascular Electrophysiology</i> , 1995, 6, 972-978.	0.8	7
119	Implantable Atrial Defibrillators. <i>Journal of Cardiovascular Electrophysiology</i> , 1995, 6, 634-648.	0.8	24
120	Transient Ischemic Attacks (TIA): Current Issues in Diagnosis and Management. <i>Journal of the American Academy of Nurse Practitioners</i> , 1995, 7, 329-338.	1.4	0
121	Silent cortical strokes associated with atrial fibrillation. <i>Clinical Cardiology</i> , 1995, 18, 573-574.	0.7	30
122	Antithrombotic agents in cerebral ischemia. <i>American Journal of Cardiology</i> , 1995, 75, 348-388.	0.7	45
123	Atrial fibrillation and anticoagulant therapy. <i>European Heart Journal</i> , 1995, 16, 302-312.	1.0	29
124	Cardiac Problems in Patients with Neurologic Disease. <i>Cardiology Clinics</i> , 1995, 13, 179-208.	0.9	24
125	Risk Factors for Bleeding during Anticoagulation. <i>Vascular Medicine Review</i> , 1995, vmr-6, 53-63.	0.2	0
126	Drugs and Surgery in the Prevention of Ischemic Stroke. <i>New England Journal of Medicine</i> , 1995, 332, 238-248.	13.9	182
127	Value of transoesophageal echocardiography before DC cardioversion in patients with atrial fibrillation: assessment of embolic risk.. <i>Heart</i> , 1995, 73, 306-309.	1.2	1
128	Prevalence, Age Distribution, and Gender of Patients With Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 1995, 155, 469.	4.3	1,709



#	ARTICLE	IF	CITATIONS
129	Physician Attitudes About Anticoagulation for Nonvalvular Atrial Fibrillation in the Elderly. Archives of Internal Medicine, 1995, 155, 277.	4.3	188
130	Antiarrhythmic Prophylaxis vs Warfarin Anticoagulation to Prevent Thromboembolic Events Among Patients With Atrial Fibrillation. Archives of Internal Medicine, 1995, 155, 913.	4.3	16
131	Oral Anticoagulants. Chest, 1995, 108, 231S-246S.	0.4	260
132	Antithrombotic Therapy for Venous Thromboembolic Disease. Chest, 1995, 108, 335S-351S.	0.4	147
133	Optimal Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Recent Cerebral Ischemia. New England Journal of Medicine, 1995, 333, 5-10.	13.9	449
134	Antithrombotic Therapy in Heart Failure: What Conclusions Can be Drawn?. European Journal of Cardiovascular Prevention and Rehabilitation, 1995, 2, 118-121.	3.1	0
135	Implementation of guidelines on stroke prevention. Family Practice, 1995, 12, 269-273.	0.8	10
136	Users' Guides to the Medical Literature. JAMA - Journal of the American Medical Association, 1995, 273, 1610.	3.8	114
137	Cost-effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients With Nonvalvular Atrial Fibrillation. JAMA - Journal of the American Medical Association, 1995, 274, 1839.	3.8	259
138	Stroke prevention.. Postgraduate Medical Journal, 1995, 71, 198-201.	0.9	1
139	Stroke and atrial fibrillation: risks, prevention and therapy in the elderly. Archives of Gerontology and Geriatrics, 1995, 20, 23-28.	1.4	1
140	Newer developments in the management of atrial fibrillation. American Heart Journal, 1995, 130, 1094-1106.	1.2	87
141	Presentation and management of patients admitted with atrial fibrillation: a review of 291 cases in a regional hospital. International Journal of Cardiology, 1995, 48, 271-278.	0.8	55
142	Meta-analytic Tools for Medical Decision Making: A Practical Guide. Medical Decision Making, 1995, 15, 81-96.	1.2	114
143	Anticoagulants in Older Patients. Drugs and Aging, 1995, 6, 45-54.	1.3	68
144	Acute Cerebral Infarction. Drugs and Aging, 1995, 6, 445-455.	1.3	6
145	Current and Future Options for the Prevention and Treatment of Stroke. CNS Drugs, 1995, 3, 351-362.	2.7	6
146	Bleeding and Thromboembolism During Anticoagulant Therapy:A Population-Based Study in Rochester, Minnesota. Mayo Clinic Proceedings, 1995, 70, 725-733.	1.4	257

#	ARTICLE	IF	CITATIONS
147	Outcomes of Warfarin Therapy: Lessons From the Real World. Mayo Clinic Proceedings, 1995, 70, 806-808.	1.4	13
148	OUTPATIENT ANTICOAGULATION ISSUES FOR THE PRIMARY CARE PHYSICIAN. Medical Clinics of North America, 1996, 80, 475-491.	1.1	10
149	Management of Atrial Fibrillation in Adults: Prevention of Thromboembolism and Symptomatic Treatment. Mayo Clinic Proceedings, 1996, 71, 150-160.	1.4	57
150	Cerebrovascular events in adult patients with cyanotic congenital heart disease. Journal of the American College of Cardiology, 1996, 28, 768-772.	1.2	159
151	The management of atrial fibrillation. American Journal of Medicine, 1996, 101, 413-421.	0.6	43
152	Cardioembolic Stroke. American Journal of Medicine, 1996, 100, 465-474.	0.6	35
153	Predictors of ischemic stroke in non-rheumatic atrial fibrillation. International Journal of Cardiology, 1996, 56, 61-70.	0.8	30
154	Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet, The, 1996, 348, 633-638.	6.3	1,045
155	PREVENTION OF THROMBOEMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION. Cardiology Clinics, 1996, 14, 537-542.	0.9	3
156	THERAPEUTIC STRATEGIES FOR ATRIAL FIBRILLATION. Cardiology Clinics, 1996, 14, 623-640.	0.9	8
157	Current Guidelines for the Treatment of Congestive Heart Failure. Drugs, 1996, 51, 89-98.	4.9	18
158	The risks and benefits of antithrombotic therapy in chronic atrial fibrillation. Medical Journal of Australia, 1996, 164, 624-626.	0.8	4
159	Atrial Fibrillation: Restoration and Maintenance of Sinus Rhythm and Indications for Anticoagulation Therapy. Annals of Internal Medicine, 1996, 125, 311.	2.0	85
160	The Utilization of Antithrombotic Prophylaxis for Atrial Fibrillation in a Geriatric Rehabilitation Hospital. Journal of the American Geriatrics Society, 1996, 44, 708-711.	1.3	17
161	The Use Of Oral Anticoagulants (Warfarin) in Older People. Journal of the American Geriatrics Society, 1996, 44, 1112-1113.	1.3	8
162	Anti-thrombotic therapy for non-rheumatic atrial fibrillation. QJM - Monthly Journal of the Association of Physicians, 1996, 89, 409-414.	0.2	4
163	Prevalence of Atrial Fibrillation and Association of Atrial Fibrillation with Prior and New Thromboembolic Stroke in Older Patients. Journal of the American Geriatrics Society, 1996, 44, 521-523.	1.3	80
164	Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. , 1996, , CD000187.		4

#	ARTICLE	IF	CITATIONS
165	The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin. <i>Annals of Internal Medicine</i> , 1996, 124, 970.	2.0	482
166	Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. <i>Journal of General Internal Medicine</i> , 1996, 11, 713-720.	1.3	114
167	Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation?. <i>Journal of General Internal Medicine</i> , 1996, 11, 721-728.	1.3	128
168	Should we just let the anticoagulation service do it?. <i>Journal of General Internal Medicine</i> , 1996, 11, 768-770.	1.3	21
169	Vascular dementia: persisting controversies and questions. <i>European Journal of Neurology</i> , 1996, 3, 299-308.	1.7	7
170	Atrial fibrillation, anticoagulation, and stroke. <i>American Journal of Cardiology</i> , 1996, 77, 38A-44A.	0.7	73
171	Maintaining Sinus Rhythm with Antifibrillatory Drugs in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 1996, 78, 67-72.	0.7	5
172	Control of heart rate during transition from intravenous to oral diltiazem in atrial fibrillation or flutter. <i>American Journal of Cardiology</i> , 1996, 78, 1246-1250.	0.7	13
173	Antithrombotic therapy in atrial fibrillation: A review of randomized trials with special reference to the stroke prevention in atrial fibrillation II (SPAF II) trial. <i>Progress in Cardiovascular Diseases</i> , 1996, 38, 337-342.	1.6	29
174	Current recommendations for the anticoagulation of patients with atrial fibrillation. <i>Progress in Cardiovascular Diseases</i> , 1996, 39, 1-20.	1.6	12
175	Transesophageal echocardiography-guided approach to cardioversion of atrial fibrillation. <i>Progress in Cardiovascular Diseases</i> , 1996, 39, 21-32.	1.6	20
176	Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: The relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast. <i>Progress in Cardiovascular Diseases</i> , 1996, 39, 57-68.	1.6	29
177	Risk of thromboembolism in new onset or transient atrial fibrillation. <i>Progress in Cardiovascular Diseases</i> , 1996, 39, 69-80.	1.6	15
178	The causes and management of atrial fibrillation. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1996, 21, 37-43.	0.7	2
179	Workshop: Reimbursement for anticoagulation services. <i>Journal of Thrombosis and Thrombolysis</i> , 1996, 2, 301-304.	1.0	2
180	The use of antithrombotic drugs for primary and secondary prevention of ischaemic stroke. <i>Reviews in Clinical Gerontology</i> , 1996, 6, 315-323.	0.5	1
181	Chronic Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 1996, 156, 2585.	4.3	154
182	Bleeding During Antithrombotic Therapy in Patients With Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 1996, 156, 409.	4.3	273

#	ARTICLE	IF	CITATIONS
183	Status of Antithrombotic Therapy for Patients With Atrial Fibrillation in University Hospitals. Archives of Internal Medicine, 1996, 156, 2311.	4.3	134
184	Routine Transesophageal Echocardiography for Cerebral Ischemia. Archives of Internal Medicine, 1996, 156, 1719.	4.3	28
185	National Patterns of Warfarin Use in Atrial Fibrillation. Archives of Internal Medicine, 1996, 156, 2537.	4.3	164
186	Length of the Hospital Stay for Mothers and Newborns. New England Journal of Medicine, 1996, 334, 1134-1135.	13.9	8
187	Severe Toxicity of Fialuridine (FIAU). New England Journal of Medicine, 1996, 334, 1135-1138.	13.9	10
188	Primary Prevention of Stroke. New England Journal of Medicine, 1996, 334, 1138-1139.	13.9	2
189	Computer-Based Patient Records. New England Journal of Medicine, 1996, 334, 1139-1140.	13.9	1
190	Sex and Swedish 85-Year-Olds. New England Journal of Medicine, 1996, 334, 1140-1141.	13.9	13
191	An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation. New England Journal of Medicine, 1996, 335, 540-546.	13.9	790
192	Atrial Fibrillation and Stroke Prevention With Warfarin in the Long-term Care Setting. Archives of Internal Medicine, 1997, 157, 978.	4.3	140
193	The Efficacy of Aspirin in Patients With Atrial Fibrillation. Archives of Internal Medicine, 1997, 157, 1237.	4.3	153
194	Review : Restoring Sinus Rhythm in Patients with Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?. Journal of Cardiovascular Pharmacology and Therapeutics, 1997, 2, 135-144.	1.0	8
195	Dalteparin in Acute Ischemic Cerebrovascular Disease: A Safety Study. Cerebrovascular Diseases, 1997, 7, 28-33.	0.8	6
196	Treating the non-electrical risks of atrial fibrillation. European Heart Journal, 1997, 18, 19-26.	1.0	7
197	Evidence-Based Medicine Holds the Key to the Future for Geriatric Medicine. Journal of the American Geriatrics Society, 1997, 45, 1268-1272.	1.3	10
198	Primary Stroke Prevention in Nonvalvular Atrial Fibrillation: Implementing the Clinical Trial Findings. Annals of Pharmacotherapy, 1997, 31, 1187-1196.	0.9	16
199	Cardioversion Guided by Transesophageal Echocardiography: The ACUTE Pilot Study: A Randomized, Controlled Trial. Annals of Internal Medicine, 1997, 126, 200.	2.0	200
200	THE MEDICAL MANAGEMENT OF ATRIAL FIBRILLATION. Cardiology Clinics, 1997, 15, 689-719.	0.9	14

#	ARTICLE	IF	CITATIONS
201	Trends and Future Developments in the Pharmacological Treatment of Acute Ischaemic Stroke. <i>Drugs</i> , 1997, 54, 9-38.	4.9	60
202	Prescribing Patterns for Nursing Home Residents in the US. <i>Drugs and Aging</i> , 1997, 11, 255-260.	1.3	26
203	Pharmacological Management of Arrhythmias in the Elderly. <i>Drugs and Aging</i> , 1997, 11, 96-110.	1.3	10
204	Is Anticoagulation Therapy Underused In Elderly Patients with Atrial Fibrillation?. <i>Drugs and Aging</i> , 1997, 10, 174-184.	1.3	15
205	Determinants of Compliance with Anticoagulation: A Case-Control Study. <i>American Journal of Medicine</i> , 1997, 103, 11-17.	0.6	230
206	Stroke prevention in patients with non-valvular atrial fibrillation: a current community perspective. <i>Journal of Clinical Neuroscience</i> , 1997, 4, 320-325.	0.8	7
207	Making decisions about medical treatment for mentally incapable adults in the UK. <i>Lancet, The</i> , 1997, 350, 950-953.	6.3	6
208	Atrial fibrillation. <i>Lancet, The</i> , 1997, 350, 943-950.	6.3	78
209	Cost-Effectiveness of Transesophageal Echocardiographic-Guided Cardioversion: A Decision Analytic Model for Patients Admitted to the Hospital With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 1997, 29, 122-130.	1.2	68
210	Thromboembolism in Chronic Atrial Flutter: Is the Risk Underestimated?. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1506-1511.	1.2	97
211	Antithrombotic treatment in chronic non-rheumatic atrial fibrillation. <i>Netherlands Journal of Medicine</i> , 1997, 51, 51-56.	0.6	0
212	Prevention of Primary Event. <i>Neurosurgery Clinics of North America</i> , 1997, 8, 165-178.	0.8	4
213	The Feasibility of a Collaborative Double-Blind Study Using an Anticoagulant. <i>Cerebrovascular Diseases</i> , 1997, 7, 100-112.	0.8	66
214	Medical and Surgical Prevention of Stroke: Experiences around the World. <i>Cerebrovascular Diseases</i> , 1997, 7, 22-28.	0.8	32
215	Atrial Fibrillation and Dilated Cardiomyopathy: Therapeutic Strategies When Sinus Rhythm Cannot be Maintained. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997, 20, 720-725.	0.5	9
216	Risk of Complications of Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997, 20, 2684-2691.	0.5	25
217	Pharmacologic Management of Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 1997, 8, 818-829.	0.8	10
218	Transthoracic Versus Transesophageal Two-Dimensional Echo Doppler Determination of Flow Velocity in the Left Atrial Appendage. <i>Echocardiography</i> , 1997, 14, 357-361.	0.3	13

#	ARTICLE	IF	CITATIONS
219	Atrial Fibrillation and Stroke. American Journal of Cardiology, 1997, 80, 11D-18D.	0.7	15
220	Atrial Fibrillation: Antiarrhythmic Therapy Versus Rate Control With Antithrombotic Therapy. American Journal of Cardiology, 1997, 80, 74C-81C.	0.7	5
221	The treatment of atrial fibrillation: Pharmacologic and nonpharmacologic strategies. Current Problems in Cardiology, 1997, 22, 37-108.	1.1	19
222	Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy. Clinical Cardiology, 1997, 20, 7-10.	0.7	30
223	Long-term management of atrial fibrillation. Clinical Cardiology, 1997, 20, 381-390.	0.7	5
224	Chronic Atrial Fibrillation: Selection of Antithrombotic Therapy. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 35-39.	0.9	1
226	From clinical trials to clinical practice: oral anticoagulation among patients with non-rheumatic, atrial fibrillation. European Journal of Clinical Pharmacology, 1997, 53, 1-5.	0.8	11
227	Spaf III Trial: Of Risk Stratification and Minimal Effective Warfarin Intensity. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 44-48.	0.9	0
228	Evolution and Revolution in Drug Labeling: Regulation of Antiarrhythmic Drugs by the Food and Drug Administration 1962-1996. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1457-1469.	0.5	5
229	Congestive cardiac failure (CCF) as a cause of fatal stroke and all cause death. Australian and New Zealand Journal of Medicine, 1998, 28, 799-804.	0.5	11
230	Anticoagulation to Prevent Stroke in Atrial Fibrillation and Its Implications for Managed Care. American Journal of Cardiology, 1998, 81, 35C-40C.	0.7	21
231	Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation—The investigators and institutions participating in the study are listed in the Appendix.. American Journal of Cardiology, 1998, 82, 433-437.	0.7	111
232	Long-term antithrombotic treatment for atrial fibrillation. American Journal of Cardiology, 1998, 82, 37N-42N.	0.7	19
233	An overview of the effect of computer-assisted management of anticoagulant therapy on the quality of anticoagulation. International Journal of Medical Informatics, 1998, 49, 311-320.	1.6	26
234	Katheterablation bei Vorhofflimmern: Schon ein Standardverfahren? (Catheter ablation for atrial) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 S31-S35.	0.3	0
235	Guidelines on oral anticoagulation: third edition. British Journal of Haematology, 1998, 101, 374-387.	1.2	381
236	A warfarin induction regimen for outpatient anticoagulation in patients with atrial fibrillation. British Journal of Haematology, 1998, 101, 450-454.	1.2	55
237	Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet, The, 1998, 352, 1167-1171.	6.3	374

#	ARTICLE	IF	CITATIONS
238	Modern Management of Prosthetic Valve Anticoagulation. Mayo Clinic Proceedings, 1998, 73, 665-680.	1.4	71
239	AGING AND CEREBROVASCULAR DISEASE. Neurologic Clinics, 1998, 16, 687-711.	0.8	36
240	EVALUATION AND MANAGEMENT OF ATRIAL FIBRILLATION IN THE EMERGENCY DEPARTMENT. Emergency Medicine Clinics of North America, 1998, 16, 389-403.	0.5	31
241	Economic Impact of Stroke and Implications for Interventions. CNS Drugs, 1998, 9, 19-39.	2.7	2
242	Treatment Strategies for Atrial Fibrillation. American Journal of Medicine, 1998, 104, 272-286.	0.6	68
243	Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin — Access the Journal Club discussion of this paper at <a href="http://www.elsevier.com/locate/ajmselect/">http://www.elsevier.com/locate/ajmselect/</a> . American Journal of Medicine, 1998, 105, 91-99.	0.6	734
244	Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I). Clinical and Applied Thrombosis/Hemostasis, 1998, 4, 51-75.	0.7	1
245	Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?. Journal of Cardiovascular Pharmacology and Therapeutics, 1998, 3, 185-194.	1.0	1
246	Anticoagulation for prevention of stroke. Neurology, 1998, 51, S20-2.	1.5	21
247	Stroke Prevention in Patients With Atrial Fibrillation: What Have We Learned?. Journal of Cardiovascular Pharmacology and Therapeutics, 1998, 3, 85-89.	1.0	1
248	Primary and Secondary Stroke Prevention in Atrial Fibrillation. Seminars in Neurology, 1998, 18, 451-459.	0.5	5
249	Atrial fibrillation: current knowledge and recommendations for management*1. European Heart Journal, 1998, 19, 1294-1320.	1.0	271
250	Cost-Effectiveness of Preference-Based Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation. Stroke, 1998, 29, 1083-1091.	1.0	96
251	Hemorrhagic Complications of Anticoagulant Treatment. Chest, 1998, 114, 511S-523S.	0.4	136
252	Antithrombotic Therapy for Venous Thromboembolic Disease. Chest, 1998, 114, 561S-578S.	0.4	184
253	Antithrombotic Therapy in Atrial Fibrillation. Chest, 1998, 114, 579S-589S.	0.4	282
254	Making Decisions About Antithrombotic Therapy in Heart Disease: Decision Analytic and Costeffectiveness Issues. Chest, 1998, 114, 699S-714S.	0.4	56
255	The effect of age and quality of life on doctors' decisions to anticoagulate patients with atrial fibrillation. Age and Ageing, 1998, 27, 285-289.	0.7	7

#	ARTICLE	IF	CITATIONS
256	Atrial Fibrillation and Thromboembolism. <i>Anesthesia and Analgesia</i> , 1998, 87, 217-223.	1.1	3
257	Recognition and Management of Cardiac Arrhythmias: Part I. General Principles and Supraventricular Tachyarrhythmias. <i>Journal of Intensive Care Medicine</i> , 1998, 13, 15-31.	1.3	0
258	Controversies Surrounding Long-term Anticoagulation of Very Elderly Patients in Atrial Fibrillation. <i>Chest</i> , 1998, 113, 1115-1118.	0.4	25
259	Antithrombotic Therapy in Valvular Heart Disease. <i>Chest</i> , 1998, 114, 590S-601S.	0.4	85
260	Recent National Patterns of Warfarin Use in Atrial Fibrillation. <i>Circulation</i> , 1998, 97, 1231-1233.	1.6	214
261	Cost-Effectiveness of Anticoagulation in Nonrheumatic Atrial Fibrillation in the Primary Prevention of Ischemic Stroke. <i>Stroke</i> , 1998, 29, 1827-1832.	1.0	67
262	Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 1998, 158, 1513.	4.3	276
263	Atrial Fibrillation and Thromboembolism. <i>Anesthesia and Analgesia</i> , 1998, 87, 217-223.	1.1	2
264	Cost-effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 1998, 158, 1669.	4.3	65
265	Oral Anticoagulants. <i>Chest</i> , 1998, 114, 445S-469S.	0.4	856
266	Thromboembolic Complication in Atrial Fibrillation in a Long-Term Follow-Up. <i>Japanese Circulation Journal</i> , 1998, 62, 255-260.	1.0	5
267	A Guide to Oral Anticoagulant Therapy. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1998, 28, 1-46.	0.5	9
268	Generic Warfarin. <i>Chest</i> , 1998, 113, 261-263.	0.4	18
269	ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 376-381.	0.5	7
270	The Anticoagulant and Antiplatelet Therapy in Cardiovascular Patients. <i>Sunhwan'gi</i> , 1999, 29, 96.	0.3	2
271	Antithrombotic therapy in heart failure: a randomized comparison of warfarin vs. aspirin (HELAS). <i>European Journal of Heart Failure</i> , 1999, 1, 419-423.	2.9	15
272	Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: outpatient management for adults. <i>American Journal of Health-System Pharmacy</i> , 1999, 56, 1505-1514.	0.5	27
273	Antithrombotic Management of Atrial Fibrillation for Stroke Prevention in Older People. <i>Clinics in Geriatric Medicine</i> , 1999, 15, 645-662.	1.0	2



#	ARTICLE	IF	CITATIONS
274	Anticoagulation after Artificial Valve Replacement with or without Atrial Fibrillation: How Much Is Really Needed?. <i>Thrombosis and Haemostasis</i> , 1999, 82, 130-135.	1.8	3
275	Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. , 1999, , CD001927.		16
276	Anticoagulant treatment of patients with atrial fibrillation in primary health care. <i>Scandinavian Journal of Primary Health Care</i> , 1999, 17, 59-63.	0.6	8
277	Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. <i>European Heart Journal</i> , 1999, 20, 979-985.	1.0	138
278	Decrease in mortality in patients with a hospital diagnosis of atrial fibrillation in Denmark during the period 1980â€“1993. <i>European Heart Journal</i> , 1999, 20, 1592-1599.	1.0	48
279	Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 1999, 159, 1322.	4.3	197
280	Reporting Risks and Benefits of Therapy by Use of the Concepts of Unqualified Success and Unmitigated Failure. <i>Circulation</i> , 1999, 99, 377-383.	1.6	45
281	Etiology and Pathogenetic Mechanisms of Optic Disc Swelling with Visual Loss. <i>Ophthalmologica</i> , 1999, 213, 40-47.	1.0	16
282	Identification and treatment of patients with atrial fibrillation in primary care. <i>Heart</i> , 1999, 81, 333-334.	1.2	6
283	Abnormalities in liver function and coagulation profile following the Fontan procedure. <i>Heart</i> , 1999, 82, 40-46.	1.2	115
284	Pharmacotherapy of atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 1999, 1, 81-96.	0.9	5
285	Fortnightly review: Anticoagulation in heart disease. <i>BMJ: British Medical Journal</i> , 1999, 318, 238-244.	2.4	20
286	Oral anticoagulation in nonvalvular atrial fibrillation. <i>Journal of Internal Medicine</i> , 1999, 245, 375-381.	2.7	11
287	Nonâ€rheumatic atrial fibrillation and stroke. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 467-472.	0.5	4
288	Atrial fibrillation: prevalence and management in an acute general medical unit. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 51-58.	0.5	31
289	Antithrombotic Therapy in Nonrheumatic/Nonvalvular Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 461-471.	0.8	3
290	Risk factors for stroke and primary prevention of stroke in atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 7, 21-26.	1.0	3
291	Very low-intensity antithrombotic therapy in atrial fibrillation. , 1999, 7, 67-71.		2

#	ARTICLE	IF	CITATIONS
292	Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis. , 1999, 7, 27-31.		12
293	Management of atrial fibrillation: out-of-hospital approach. , 1999, 7, 131-135.		1
294	Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits. , 1999, 7, 61-65.		3
295	Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 7, 157-163.	1.0	29
296	Outcome of valve repair and the cox maze procedure for mitral regurgitation and associated atrial fibrillation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1999, 118, 628-635.	0.4	156
297	Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1999, 118, 833-840.	0.4	321
298	Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation. <i>Contemporary Clinical Trials</i> , 1999, 20, 386-393.	2.0	9
299	Discussion. <i>American Journal of Cardiology</i> , 1999, 84, 698-700.	0.7	35
300	Safety of Treatment with Oral Anticoagulants in the Elderly. <i>Drugs and Aging</i> , 1999, 14, 303-312.	1.3	86
301	Epidemiology of Adverse Drug Reactions in the Elderly by Drug Class. <i>Drugs and Aging</i> , 1999, 14, 231-239.	1.3	99
302	Cardioversion in Patients with Atrial Fibrillation and Left Atrial Thrombi on Initial Transesophageal Echocardiography: Should Transesophageal Echocardiography Be Repeated Before Elective Cardioversion? A Cost-Effectiveness Analysis. <i>Journal of the American Society of Echocardiography</i> , 1999, 12, 508-516.	1.2	21
303	Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 1999, 131, 492.	2.0	1,442
304	Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. <i>American Heart Journal</i> , 1999, 137, 307-312.	1.2	82
305	ATRIAL FIBRILLATION IN THE ELDERLY. <i>Cardiology Clinics</i> , 1999, 17, 173-188.	0.9	19
307	Guidelines for Stroke Prevention in Patients with Atrial Fibrillation. <i>Drugs</i> , 1999, 58, 997-1009.	4.9	18
308	Outcomes of Long-Term Anticoagulation in Frail Elderly Patients with Atrial Fibrillation. <i>Clinical Drug Investigation</i> , 1999, 17, 483-488.	1.1	8
310	Assimilating new therapeutic interventions into clinical practice: How does hypertension compare with other therapeutic areas?. <i>American Heart Journal</i> , 1999, 138, S256-S260.	1.2	13
311	Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. <i>American Journal of Medicine</i> , 1999, 106, 165-171.	0.6	98

#	ARTICLE	IF	CITATIONS
312	Anticoagulation in atrial fibrillation in older people. <i>British Journal of Hospital Medicine</i> , 1999, 60, 398-399.	0.3	0
313	Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 1999, 130, 625.	2.0	57
314	The influence of randomized trials on the use of anticoagulants for atrial fibrillation. <i>Age and Ageing</i> , 1999, 28, 441-446.	0.7	14
315	MANAGEMENT OF ATRIAL FIBRILLATION, VENTRICULAR ARRHYTHMIAS AND PACEMAKERS IN OLDER PERSONS: Series Editor: Wilbert S. Aronow, MD: Management of the Older Person With Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 740-748.	1.3	25
316	Anticoagulation in Neurosurgical Patients. <i>Neurosurgery</i> , 1999, 45, 838-848.	0.6	53
317	Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. <i>Annals of Internal Medicine</i> , 1999, 131, 927.	2.0	522
318	Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. <i>BMJ: British Medical Journal</i> , 1999, 319, 958-964.	2.4	200
319	Preventing Stroke in Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 1830.	3.8	135
320	Improving Management of Atrial Fibrillation and Anticoagulation in a Community Hospital. <i>The Joint Commission Journal on Quality Improvement</i> , 2000, 26, 18-28.	1.5	20
321	A Multicomponent Intervention To Prevent Major Bleeding Complications in Older Patients Receiving Warfarin. <i>Annals of Internal Medicine</i> , 2000, 133, 687.	2.0	303
322	Use of Ambulatory Electrocardiography for the Detection of Paroxysmal Atrial Fibrillation in Patients with Stroke. <i>Canadian Journal of Neurological Sciences</i> , 2000, 27, 25-31.	0.3	39
323	Prediction of Embolism in Atrial Fibrillation. <i>Japanese Circulation Journal</i> , 2000, 64, 411-415.	1.0	39
324	Prevalence and Clinical Characteristics of Patients With Atrial Fibrillation. <i>Japanese Circulation Journal</i> , 2000, 64, 653-658.	1.0	73
325	Implementation of antithrombotic management in atrial fibrillation. <i>Postgraduate Medical Journal</i> , 2000, 76, 783-786.	0.9	9
326	Which Acute Stroke Patients with Atrial Fibrillation are Prescribed Warfarin Therapy? Results from One-Year's Experience in Dundee. <i>Scottish Medical Journal</i> , 2000, 45, 110-112.	0.7	1
327	Intracerebral Haemorrhages and Oral Anticoagulation in the North of Scotland. <i>Scottish Medical Journal</i> , 2000, 45, 101-104.	0.7	12
328	Anticoagulant use in nonvalvular atrial fibrillation. <i>Postgraduate Medicine</i> , 2000, 108, 113-126.	0.9	5
329	The Use of Oral Anticoagulants (warfarin) in Older People. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 224-227.	1.3	38

#	ARTICLE	IF	CITATIONS
330	Adverse Outcomes and Predictors of Underuse of Antithrombotic Therapy in Medicare Beneficiaries With Chronic Atrial Fibrillation. <i>Stroke</i> , 2000, 31, 822-827.	1.0	280
331	Warfarin for Stroke Prevention Still Underused in Atrial Fibrillation. <i>Stroke</i> , 2000, 31, 1217-1222.	1.0	121
332	Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2000, 31, 817-821.	1.0	278
333	Clinical implication of antiembolic trials in atrial fibrillation and role of transesophageal echocardiography in atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2000, 15, 58-63.	0.8	5
334	Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. <i>BMJ: British Medical Journal</i> , 2000, 320, 1236-1239.	2.4	131
335	The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. <i>Journal of General Internal Medicine</i> , 2000, 15, 31-37.	1.3	77
336	Prevention of thromboembolism in atrial fibrillation. <i>Journal of General Internal Medicine</i> , 2000, 15, 56-67.	1.3	108
337	Transesophageal Echocardiography Risk Factors for Stroke in Nonvalvular Atrial Fibrillation. <i>Echocardiography</i> , 2000, 17, 365-372.	0.3	14
338	Risk of Thromboembolism in Acute Atrial Fibrillation or Atrial Flutter. <i>Echocardiography</i> , 2000, 17, 393-405.	0.3	26
339	Adequacy of Anticoagulation in Patients with Atrial Fibrillation Coming to a Hospital. <i>Pharmacotherapy</i> , 2000, 20, 1060-1065.	1.2	63
340	Atrial fibrillation: Epidemiology, mechanisms, and management. <i>Current Problems in Cardiology</i> , 2000, 25, 413-524.	1.1	16
341	Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a veterans affairs medical center. <i>American Journal of Cardiology</i> , 2000, 85, 568-572.	0.7	76
342	Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 13-19.	1.0	35
343	Anticoagulation therapy for atrial fibrillation and coronary disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 47-51.	1.0	1
344	Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 283-292.	1.0	133
346	Cardiomyopathy and embolization: risks and benefits of anticoagulation in sinus rhythm. <i>Current Cardiology Reports</i> , 2000, 2, 106-111.	1.3	3
348	ENS Communications. <i>Journal of Neurology</i> , 2000, 247, 729-749.	1.8	0
349	Incidence of Atrial Fibrillation and Cerebral Stroke in Patients Treated with Ventricular Pacing and Dual-Chamber Pacing. <i>Sunhwan'gi</i> , 2000, 30, 751.	0.3	0

#	ARTICLE	IF	CITATIONS
350	The potential use of decision analysis to support shared decision making in the face of uncertainty: the example of atrial fibrillation and warfarin anticoagulation. <i>Quality in Health Care: QHC</i> , 2000, 9, 238-244.	1.2	29
351	Evaluating Quality of Care for Patients With Heart Failure. <i>Circulation</i> , 2000, 101, E122-40.	1.6	130
352	Effect and Outcomes of The Asge Guidelines on The Periendoscopic Management of Patients Who Take Anticoagulants. <i>American Journal of Gastroenterology</i> , 2000, 95, 1717-1724.	0.2	40
353	Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion. <i>European Heart Journal</i> , 2000, 21, 837-847.	1.0	59
354	Incidence, Predictive Factors, and Prognostic Significance of Supraventricular Tachyarrhythmias in Congestive Heart Failure. <i>Chest</i> , 2000, 118, 914-922.	0.4	133
355	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 266-284.	0.9	18
356	Why Do Patients With Atrial Fibrillation Not Receive Warfarin?. <i>Archives of Internal Medicine</i> , 2000, 160, 41.	4.3	509
357	Stroke Prevention as an Indication for the Maze Procedure in the Treatment of Atrial Fibrillation. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2000, 12, 56-62.	0.4	48
358	Stroke: Management and Rehabilitation. <i>Angiology</i> , 2000, 51, 977-984.	0.8	3
359	Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. <i>American Heart Journal</i> , 2000, 139, 752-760.	1.2	13
360	Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation. <i>American Journal of Medicine</i> , 2000, 108, 36-40.	0.6	87
362	Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. <i>American Heart Journal</i> , 2000, 140, 886-890.	1.2	150
363	Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. <i>Lancet, The</i> , 2000, 355, 956-962.	6.3	170
364	Use of Oral Anticoagulants in Older Patients. <i>Drugs and Aging</i> , 2000, 16, 409-435.	1.3	35
365	Cost Effectiveness of Therapies for Atrial Fibrillation. <i>Pharmacoeconomics</i> , 2000, 18, 317-333.	1.7	8
368	CLINICAL TRIALS OF PACING MODE SELECTION. <i>Cardiology Clinics</i> , 2000, 18, 1-23.	0.9	21
369	MANAGEMENT OF ARRHYTHMIAS. <i>Clinics in Geriatric Medicine</i> , 2000, 16, 593-618.	1.0	7
371	Heparin and oral anticoagulants in the treatment of brain ischemia. <i>Journal of the Neurological Sciences</i> , 2000, 173, 3-9.	0.3	19

#	ARTICLE	IF	CITATIONS
372	Treatment of underlying atrial fibrillation: paced rhythm obscures recognition. <i>Journal of the American College of Cardiology</i> , 2000, 36, 784-787.	1.2	33
373	Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2001, 37, 691-704.	1.2	141
374	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation <sup>31</sup> This document was approved by the American College of Cardiology Board of Trustees in August 2001, the American Heart Association Science Advisory and Coordinating Committee in August 2001, and the European Society of Cardiology Board and Committee for Practice Guidelines and Policy Conferences in August 2001. <sup>32</sup> When citing this document, the American College of Cardiology, the American Heart Association, and the European Society. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1266.	1.2	62
375	Seasonal control of warfarin therapy. <i>American Journal of Medicine</i> , 2001, 111, 332.	0.6	2
376	Evolving role of echocardiography in the management of atrial fibrillation. <i>American Heart Journal</i> , 2001, 141, 518-527.	1.2	8
377	A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation. <i>Clinical Therapeutics</i> , 2001, 23, 1628-1636.	1.1	15
381	Hemorrhagic complications of oral anticoagulant therapy. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 49-56.	1.0	28
382	Evaluation and Management of Atrial Fibrillation. <i>Medical Clinics of North America</i> , 2001, 85, 225-244.	1.1	21
383	Antithrombotic therapy in atrial fibrillation. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 131-147.	1.0	15
384	Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation. <i>CNS Drugs</i> , 2001, 15, 623-631.	2.7	15
385	Atrial Fibrillation in Stroke Prevention.. <i>Nosotchu</i> , 2001, 23, 275-279.	0.0	0
386	A Benefit/Risk Analysis of the Prevention of Brain Ischaemia with Anticoagulant Drugs: When, How and Whom to Treat?. <i>Cerebrovascular Diseases</i> , 2001, 11, 100-104.	0.8	0
387	Underutilization of Anticoagulation Therapy in Chronic Atrial Fibrillation.. <i>International Heart Journal</i> , 2001, 42, 55-65.	0.6	16
388	Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding. <i>Thrombosis and Haemostasis</i> , 2001, 85, 418-422.	1.8	138
389	Nonvalvular atrial fibrillation and stroke prevention. <i>Medical Journal of Australia</i> , 2001, 174, 234-239.	0.8	48
390	Stroke prophylaxis in nonvalvular atrial fibrillation<. <i>Current Opinion in Neurology</i> , 2001, 14, 59-65.	1.8	3
391	Anticoagulation in the elderly. <i>Current Opinion in Pulmonary Medicine</i> , 2001, 7, 365-370.	1.2	13
392	Anticoagulation in the Ambulatory Patient: Basic Principles and Current Concepts in Warfarin Therapy. <i>Topics in Geriatric Rehabilitation</i> , 2001, 17, 18-37.	0.2	3

#	ARTICLE	IF	CITATIONS
393	Instability of Anticoagulation Intensity Contributes to Occurrence of Ischemic Stroke in Patients With Non-Rheumatic Atrial Fibrillation.. Japanese Circulation Journal, 2001, 65, 404-408.	1.0	18
394	Cost-Effectiveness of Antiarrhythmic Drugs for Prevention of Thromboembolism in Patients With Paroxysmal Atrial Fibrillation.. Japanese Circulation Journal, 2001, 65, 765-768.	1.0	6
395	Antithrombotic Therapy in Atrial Fibrillation. Chest, 2001, 119, 194S-206S.	0.4	406
396	Managing Oral Anticoagulant Therapy. Chest, 2001, 119, 22S-38S.	0.4	525
397	Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. , 2001, , CD001938.		25
398	Antithrombotic Therapy in Valvular Heart Disease. Chest, 2001, 119, 207S-219S.	0.4	56
399	Are the Results of Randomized Controlled Trials on Anticoagulation in Patients With Atrial Fibrillation Generalizable to Clinical Practice?. Archives of Internal Medicine, 2001, 161, 1443.	4.3	104
400	A Survey of Long-Term Antiarrhythmic Therapy in Elderly Patients with Atrial Fibrillation. Journal of Pharmacy Practice and Research, 2001, 31, 93-97.	0.2	3
401	Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients With Atrial Fibrillation?. Stroke, 2001, 32, 2828-2832.	1.0	89
402	Primary Prevention of Ischemic Stroke. Stroke, 2001, 32, 280-299.	1.0	512
403	Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation. Stroke, 2001, 32, 2246-2252.	1.0	62
404	Oral anticoagulant treatment in very elderly patients with atrial fibrillation. Comprehensive Therapy, 2001, 27, 7-10.	0.2	4
405	Choices in medical management for prevention of acute ischemic stroke. Current Neurology and Neuroscience Reports, 2001, 1, 33-38.	2.0	3
406	Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people. Archives of Gerontology and Geriatrics, 2001, 33, 219-226.	1.4	30
407	Near-patient testing devices to monitor oral anticoagulant therapy. British Journal of Haematology, 2001, 113, 847-852.	1.2	41
408	Primary stroke prevention. European Journal of Neurology, 2001, 8, 1-15.	1.7	36
409	Special Considerations for the Elderly Patient with Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 243-253.	0.9	0
410	The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines. American Journal of Transplantation, 2001, 1, 1-95.	2.6	14

#	ARTICLE	IF	CITATIONS
411	Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting. <i>Archives of Internal Medicine</i> , 2001, 161, 2458-2463.	4.3	166
412	Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population With Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2001, 161, 2125.	4.3	99
413	Prevention of Cerebral Thromboembolism by Low-Dose Anticoagulant Therapy in Atrial Fibrillation with Mitral Regurgitation. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 37, 422-426.	0.8	11
414	Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. <i>Chest</i> , 2001, 119, 8S-21S.	0.4	862
415	Hemorrhagic Complications of Anticoagulant Treatment. <i>Chest</i> , 2001, 119, 108S-121S.	0.4	672
416	Primary Prevention of Ischemic Stroke. <i>Circulation</i> , 2001, 103, 163-182.	1.6	340
417	Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	1.0	448
418	the North American Society of Pacing and Electrophysiology. <i>European Heart Journal</i> , 2001, 22, 1852-1923. HEARTâ€“BRAIN RELATIONSHIP: ATRIAL FIBRILLATION AND STROKE. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 493-499.	0.5	9
419	Effects of Anticoagulation on Infarct Size and Clinical Outcome in Acute Cardioembolic Stroke. <i>Angiology</i> , 2002, 53, 551-556.	0.8	25
420	Evaluation of clinical treatment of atrial fibrillation associated with rheumatic mitral valve disease by radiofrequency ablation. <i>European Journal of Cardio-thoracic Surgery</i> , 2002, 21, 249-254.	0.6	31
421	Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2441.	3.8	632
422	Atrial Fibrillation. <i>Heart Disease (Hagerstown, Md )</i> , 2002, 4, 91-101.	1.3	12
423	Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. <i>American Journal of Medicine</i> , 2002, 113, 42-51.	0.6	131
424	Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2002, 39, 301-307.	1.2	329
425	Atrial Fibrillation in the Elderly. <i>Drugs and Aging</i> , 2002, 19, 819-846.	1.3	58
426	Prospective evaluation of the quality of oral anticoagulation management in an outpatient clinic and in general practices. <i>Thrombosis Research</i> , 2002, 105, 103-108.	0.8	11
427	The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. <i>Journal of Clinical Neuroscience</i> , 2002, 9, 268-272.	0.8	26
428	Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study. <i>American Heart Journal</i> , 2002, 143, 991-1001.	1.2	157



#	ARTICLE	IF	CITATIONS
430	La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999. Revista Espanola De Cardiología, 2002, 55, 943-952.	0.6	59
432	Cambios en el perfil clínico de los pacientes anticoagulados durante la década de los noventa. Revista Espanola De Cardiología, 2002, 55, 55-60.	0.6	10
433	Principles of drug therapy in older patients: rational drug prescribing. Clinics in Geriatric Medicine, 2002, 18, 577-592.	1.0	54
436	Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. Journal of Internal Medicine, 2002, 252, 64-69.	2.7	35
437	Deciding on Anticoagulating the Oldest Old with Atrial Fibrillation: Insights from Cost-Effectiveness Analysis. Journal of the American Geriatrics Society, 2002, 50, 863-869.	1.3	36
438	The impact of age on antithrombotic use in elderly patients with non-valvular atrial fibrillation. Australasian Journal on Ageing, 2002, 21, 36-41.	0.4	28
439	Anticoagulants for atrial fibrillation: Why is the treatment rate so low?. Clinical Cardiology, 2002, 25, 447-454.	0.7	66
440	Anti-thrombotic strategies for patients with atrial fibrillation and heart failure. Heart Failure Reviews, 2002, 7, 261-266.	1.7	5
441	Problems, interventions and complications in long-term oral anticoagulation therapy. Journal of Thrombosis and Thrombolysis, 2002, 14, 65-72.	1.0	6
442	Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans. Clinical Pharmacology and Therapeutics, 2002, 71, 368-374.	2.3	28
443	Age and First INR After Initiation of Oral Anticoagulant Therapy with Acenocoumarol Predict the Maintenance Dosage. Journal of Thrombosis and Thrombolysis, 2003, 15, 197-203.	1.0	6
444	Physicians' Attitudes and the Use of Oral Anticoagulants: Surveying the Present and Envisioning Future. Journal of Thrombosis and Thrombolysis, 2003, 16, 33-37.	1.0	9
445	Randomized clinical trials of antithrombotic therapy in atrial fibrillation: Update 2003. Seminars in Cerebrovascular Diseases and Stroke, 2003, 3, 38-42.	0.1	0
446	Pharmacologic management of atrial fibrillation in the elderly: Rate control, rhythm control, and anticoagulation. Current Cardiology Reports, 2003, 5, 380-386.	1.3	1
447	Oral Anticoagulants vs. Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Verdict is in. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 374-378.	0.9	7
448	Do Anticoagulation Management Services Improve Care? Implications of the Managing Anticoagulation Services Trial. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 379-381.	0.9	12
449	Use of Subcutaneous Enoxaparin Compared to Intravenous Heparin and Oral Phenprocoumon in the Setting of Cardioversion—The ACE Study (Anticoagulation in Cardioversion Using Enoxaparin). Journal of Interventional Cardiac Electrophysiology, 2003, 7, 382-386.	0.9	0
450	Quality of Blood Pressure Control and Risk of Cerebral Bleeding in Patients with Oral Anticoagulation. Vienna Clinical Weekly, 2003, 30, 6-9.	0.9	4

#	ARTICLE	IF	CITATIONS
452	Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 320-328.	1.7	36
453	Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. <i>Journal of General Internal Medicine</i> , 2003, 18, 903-907.	1.3	8
454	Combined Antiplatelet Therapy in Atrial Fibrillation:. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S60-S63.	0.8	34
455	Prevention of Vascular Events in Patients with Atrial Fibrillation:. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S52-S55.	0.8	7
457	Coumarin therapy in thrombosis. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 201-216.	0.9	17
460	Choice of prosthetic heart valve for adult patients. <i>Journal of the American College of Cardiology</i> , 2003, 41, 893-904.	1.2	266
461	Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1445-1451.	1.2	193
462	American Heart Association/American College of Cardiology Foundation guide to warfarin therapy <sup>11</sup> The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1633-1652.	1.2	314
463	Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. <i>Thrombosis Research</i> , 2003, 111, 137-142.	0.8	159
464	Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. <i>International Journal of Cardiology</i> , 2003, 87, 135-139.	0.8	76
465	Ought dialysis patients with atrial fibrillation be treated with anticoagulants?. <i>International Journal of Cardiology</i> , 2003, 87, 139-141.	0.8	14
466	Preventing stroke in patients with atrial fibrillation: Current treatments and new concepts. <i>American Heart Journal</i> , 2003, 145, 418-423.	1.2	32
467	American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. <i>Circulation</i> , 2003, 107, 1692-1711.	1.6	593
468	Primary and Secondary Stroke Prevention in Nonrheumatic Atrial Fibrillation by Oral Anticoagulation. <i>European Neurology</i> , 2003, 50, 127-135.	0.6	5
469	Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999. <i>Circulation</i> , 2003, 108, 711-716.	1.6	493
470	Pharmacotherapy of Atrial Fibrillation. <i>Asian Cardiovascular and Thoracic Annals</i> , 2003, 11, 364-374.	0.2	3
471	Rising Rates of Hospital Admissions for Atrial Fibrillation. <i>Epidemiology</i> , 2003, 14, 666-672.	1.2	253
472	Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2685.	3.8	635

#	ARTICLE	IF	CITATIONS
473	Anticoagulation in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 243-250.	0.7	16
474	Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. <i>Seminars in Vascular Medicine</i> , 2003, 03, 333-338.	2.1	1
475	Anticoagulation in atrial fibrillation: what is certain and what is to come. <i>European Heart Journal Supplements</i> , 2003, 5, H45-H50.	0.0	3
476	Design, Progress and Challenges of a Double-Blind Trial of Warfarin versus Aspirin for Symptomatic Intracranial Arterial Stenosis. <i>Neuroepidemiology</i> , 2003, 22, 106-117.	1.1	122
477	Anticoagulation Management Strategies in Patients with Atrial Fibrillation. <i>Critical Pathways in Cardiology</i> , 2003, 2, 178-187.	0.2	0
479	Predictors of Warfarin Use Among Ohio Medicaid Patients With New-Onset Nonvalvular Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2003, 163, 1705.	4.3	66
480	Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians. <i>Annals of Internal Medicine</i> , 2003, 139, 1009.	2.0	130
481	Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography. <i>Annals of Internal Medicine</i> , 2003, 139, 1018.	2.0	182
482	Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose. <i>Thrombosis and Haemostasis</i> , 2004, 91, 394-402.	1.8	33
483	New advances in stroke prevention in atrial fibrillation: ximelagatran and direct thrombin inhibition. <i>European Heart Journal Supplements</i> , 2004, 6, B20-B24.	0.0	2
484	Cerebrovascular Risk Factors and Clinical Classification of Strokes. <i>Seminars in Vascular Medicine</i> , 2004, 4, 287-303.	2.1	60
485	Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. <i>Heart</i> , 2004, 90, 1259-1262.	1.2	26
486	Cardiac tumour in a neonate with left ventricular outflow tract obstruction. <i>Heart</i> , 2004, 90, 881-881.	1.2	3
487	Establishing an Optimal Therapeutic Range for Coumarins. <i>Archives of Internal Medicine</i> , 2004, 164, 588.	4.3	8
488	Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan. <i>Journal of Medical Screening</i> , 2004, 11, 97-102.	1.1	28
489	Role of oral anticoagulation in management of atrial fibrillation. <i>British Heart Journal</i> , 2004, 90, 813-817.	2.2	33
490	Control of Heart Rate Versus Rhythm in Rheumatic Atrial Fibrillation: A Randomized Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004, 9, 65-73.	1.0	81
491	The Pharmacology and Management of the Vitamin K Antagonists. <i>Chest</i> , 2004, 126, 204S-233S.	0.4	1,092

#	ARTICLE	IF	CITATIONS
492	Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation. <i>Chest</i> , 2004, 126, 1938-1945.	0.4	260
493	Antithrombotic Therapy in Valvular Heart Disease—Native and Prosthetic. <i>Chest</i> , 2004, 126, 457S-482S.	0.4	333
494	Recent trials in atrial fibrillation: lessons learned beyond rate and rhythm. <i>European Heart Journal Supplements</i> , 2004, 6, B15-B19.	0.0	2
495	Rapid access arrhythmia clinic for the diagnosis and management of new arrhythmias presenting in the community: a prospective, descriptive study. <i>Heart</i> , 2004, 90, 877-881.	1.2	12
496	Chapter 5 Cardioembolic Stroke. <i>Blue Books of Practical Neurology</i> , 2004, 29, 79-98.	0.1	0
497	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. <i>Circulation</i> , 2004, 109, 672-693.	1.6	685
499	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, e29-50.	1.1	118
500	Between the Devil and the Deep Blue Sea—balancing the risks and potential benefits of warfarin for older people with atrial fibrillation. <i>Age and Ageing</i> , 2004, 33, 544-547.	0.7	5
501	Percutaneous pulmonary vein isolation for treatment of atrial fibrillation. <i>Internal Medicine Journal</i> , 2004, 34, 453-457.	0.5	3
502	Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 798-806.	1.1	90
503	Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. <i>Journal of Internal Medicine</i> , 2004, 256, 137-144.	2.7	59
504	Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1637-1644.	1.9	64
505	Stroke Prophylaxis in Institutionalized Elderly Patients with Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 428-433.	1.3	42
506	Anticoagulant Use for Atrial Fibrillation in the Elderly. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1151-1156.	1.3	106
507	The Use of a Modified Sphygmomanometer to Detect Atrial Fibrillation in Outpatients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2004, 27, 639-643.	0.5	49
508	Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. <i>European Journal of Haematology</i> , 2004, 73, 227-242.	1.1	7
509	Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). <i>American Journal of Cardiology</i> , 2004, 94, 889-894.	0.7	227
510	Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (The Tj ETQq1 1 0.784314 rgBT /Overbo	0.7	86

#	ARTICLE	IF	CITATIONS
511	Do Population Studies Confirm the Benefit of Oral Anticoagulation in Atrial Fibrillation Demonstrated in Clinical Trials?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2004, 10, 9-16.	0.6	9
512	Why is Warfarin Underutilized in Patients with Atrial Fibrillation?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2004, 10, 21-25.	0.6	8
513	The decision to anticoagulate: Assessing whether benefits outweigh the risks for patients with atrial fibrillation. <i>Clinical Cardiology</i> , 2004, 27, 313-320.	0.7	5
515	Anticoagulation for non-valvular atrial fibrillation – towards a new beginning with ximelagatran. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2004, 5, 3.	1.5	4
516	BEHAVIORAL DISTURBANCES IN ALZHEIMER'S DISEASE: A NON-PHARMACOLOGICAL THERAPEUTIC APPROACH. <i>Archives of Gerontology and Geriatrics</i> , 2004, 38, 379-386.	1.4	9
517	Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. <i>The Cochrane Library</i> , 2004, , CD000185.	1.5	61
518	The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2004, 79, 904-913.	1.4	41
520	Anticoagulation for atrial fibrillation. <i>Cardiology Clinics</i> , 2004, 22, 47-62.	0.9	11
522	Mortality as an endpoint in atrial fibrillation. <i>Heart Rhythm</i> , 2004, 1, 8-19.	0.3	41
525	Surgical Treatment of Atrial Fibrillation. <i>Heart Lung and Circulation</i> , 2004, 13, 280-287.	0.2	11
526	Atrial Fibrillation, Stroke and Anticoagulant Use. <i>Heart Lung and Circulation</i> , 2004, 13, 252-255.	0.2	1
528	Evidence-based guidelines for cardiovascular disease prevention in women. <i>Journal of the American College of Cardiology</i> , 2004, 43, 900-921.	1.2	94
529	Prevention. <i>Cerebrovascular Diseases</i> , 2004, 17, 15-29.	0.8	59
530	Newly Diagnosed Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2004, 351, 2408-2416.	13.9	115
531	Trends in utilization of antithrombotic therapy in patients with atrial fibrillation before stroke onset in a community-based study, from 1985 through 1997. <i>Preventive Medicine</i> , 2004, 38, 121-128.	1.6	20
532	Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients. <i>International Journal of Cardiology</i> , 2004, 96, 89-95.	0.8	12
533	The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. <i>American Journal of Medicine</i> , 2004, 116, 451-459.	0.6	28
534	Non-valvular atrial fibrillation and stroke: Implications for nursing practice and therapeutics. <i>Australian Critical Care</i> , 2004, 17, 65-73.	0.6	3

#	ARTICLE	IF	CITATIONS
535	Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. The Cochrane Library, 2004, , CD000187.	1.5	68
536	Limitations to antiarrhythmic drug use in patients with atrial fibrillation. Cmaj, 2004, 171, 741-745.	0.9	23
537	Antithrombotic Therapy in Atrial Fibrillation. Chest, 2004, 126, 429S-456S.	0.4	519
538	Hemorrhagic Complications of Anticoagulant Treatment. Chest, 2004, 126, 287S-310S.	0.4	452
539	Physicians' Attitudes Toward Anticoagulant Therapy in Patients with Chronic Atrial Fibrillation. Internal Medicine, 2004, 43, 553-560.	0.3	18
540	Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. The Cochrane Library, 2005, , CD001927.	1.5	113
541	Ximelagatran Cost Effectiveness for Stroke Prevention in Atrial Fibrillation. Journal of Pharmacy Practice and Research, 2005, 35, 279-283.	0.5	2
542	Differences in quality of care among patients hospitalized with atrial fibrillation as primary or secondary cause for admission. International Journal for Quality in Health Care, 2005, 17, 255-258.	0.9	6
543	Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. Journal of Thrombosis and Haemostasis, 2005, 3, 1218-1223.	1.9	57
544	Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. Journal of General Internal Medicine, 2005, 20, 1114-1119.	1.3	43
545	Management of atrial fibrillation. Current Problems in Cardiology, 2005, 30, 175-233.	1.1	30
546	Arritmias y electrofisiología cardíaca: temas de actualidad en 2004. Revista Espanola De Cardiologia Suplementos, 2005, 5, 55A-65A.	0.2	0
547	Epidemiological Profile of Atrial Fibrillation: A Contemporary Perspective. Progress in Cardiovascular Diseases, 2005, 48, 1-8.	1.6	94
548	Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation. Progress in Cardiovascular Diseases, 2005, 48, 108-124.	1.6	11
549	New treatment options for stroke prevention in atrial fibrillation. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 341-349.	0.4	0
550	Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 241-250.	0.4	5
551	The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481â€”The Home INR Study (THINRS). Journal of Thrombosis and Thrombolysis, 2005, 19, 163-172.	1.0	25
552	Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study. Thrombosis Journal, 2005, 3, 20.	0.9	6

#	ARTICLE	IF	CITATIONS
554	Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making. <i>Medical Decision Making</i> , 2005, 25, 548-559.	1.2	67
555	An Argument for Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. <i>Circulation</i> , 2005, 111, 3150-3156.	1.6	26
556	Rate Control Is Preferable to Rhythm Control in the Majority of Patients With Atrial Fibrillation. <i>Circulation</i> , 2005, 111, 3141-3150.	1.6	41
557	Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. <i>Postgraduate Medical Journal</i> , 2005, 81, 370-375.	0.9	3
558	Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study. <i>Archives of Internal Medicine</i> , 2005, 165, 1185.	4.3	207
559	Prevention of Stroke in Patients with Atrial Fibrillation. <i>Seminars in Vascular Medicine</i> , 2005, 5, 285-292.	2.1	23
560	Antithrombotic Therapy Practices in US Hospitals in an Era of Practice Guidelines. <i>Archives of Internal Medicine</i> , 2005, 165, 1458.	4.3	145
561	Anticoagulation in nonvalvular atrial fibrillation. <i>Future Cardiology</i> , 2005, 1, 373-380.	0.5	1
562	Anticoagulation for Atrial Fibrillation in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2005, 14, 81-86.	0.7	6
563	The Epidemiology of Atrial Fibrillation in Elderly Persons: The Tip of the Iceberg. <i>The American Journal of Geriatric Cardiology</i> , 2005, 14, 56-61.	0.7	107
564	Will this be the End of the Anticoagulation Clinic for Patients with Atrial Fibrillation?. <i>Current Drug Targets Cardiovascular &amp; Haematological Disorders</i> , 2005, 5, 405-408.	2.0	2
565	Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 699.	3.8	138
566	Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000. <i>Stroke</i> , 2005, 36, 2362-2366.	1.0	98
567	Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. <i>Current Medical Research and Opinion</i> , 2005, 21, 1583-1594.	0.9	56
568	Current status of stroke prevention in patients with atrial fibrillation. <i>Country Review Ukraine</i> , 2005, 7, C12-C18.	0.8	6
569	Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. <i>Country Review Ukraine</i> , 2005, 7, C34-C40.	0.8	14
570	Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. <i>Country Review Ukraine</i> , 2005, 7, C28-C33.	0.8	11
572	How many patients in atrial fibrillation admitted to an acute medical unit will benefit from oral anticoagulation?. <i>European Journal of Internal Medicine</i> , 2005, 16, 97-104.	1.0	1

#	ARTICLE	IF	CITATIONS
573	Atrial Fibrillation: Modern Concepts and Management. Annual Review of Medicine, 2005, 56, 475-494.	5.0	15
575	A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. Journal of Clinical Epidemiology, 2005, 58, 26-40.	2.4	49
576	Direct thrombin inhibitors: Stroke prevention in atrial fibrillation and potential anti-inflammatory properties. American Heart Journal, 2005, 149, S32-S35.	1.2	3
577	Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. American Heart Journal, 2005, 149, 650-656.	1.2	190
578	Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. American Journal of Medicine, 2005, 118, 612-617.	0.6	294
581	Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation. Journal of the American College of Cardiology, 2005, 46, 1729-1736.	1.2	360
582	Trials and Tribulations of Non-Inferiority. Journal of the American College of Cardiology, 2005, 46, 1986-1995.	1.2	104
584	Ximelagatran for stroke prevention in atrial fibrillation. Expert Review of Cardiovascular Therapy, 2005, 3, 551-563.	0.6	6
585	Pharmacological Prevention of Thromboembolism in Patients with Left Ventricular Dysfunction. American Journal of Cardiovascular Drugs, 2006, 6, 41-49.	1.0	10
586	Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet, The, 2006, 367, 404-411.	6.3	385
587	Quality Improvement Case Study: Warfarin Sodium Interactions. Journal of the American Medical Directors Association, 2006, 7, 315-318.	1.2	8
588	Antithrombotic Therapy in Atrial Fibrillation. Clinics in Geriatric Medicine, 2006, 22, 155-166.	1.0	6
589	Anticoagulation practice in cardiac electrophysiology. Heart Rhythm, 2006, 3, 372-374.	0.3	3
590	Management of Arrhythmias in the Emergency Department. Cardiology Clinics, 2006, 24, 125-133.	0.9	11
591	Natural History of and Risk Factors for Idiopathic Atrial Fibrillation Recurrence (FAP Registry). Revista Espanola De Cardiologia (English Ed ), 2006, 59, 1106-1112.	0.4	4
592	Compliance-Guided Therapy. Clinical Pharmacokinetics, 2006, 45, 95-104.	1.6	11
594	ACC/AHA/ESC: Guías de Práctica Clínica 2006 para el manejo de pacientes con fibrilación auricular. Versión resumida. Revista Espanola De Cardiologia, 2006, 59, 1329.e1-1329.e64.	0.6	15
595	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation Executive Summary. Journal of the American College of Cardiology, 2006, 48, 854-906.	1.2	1,044



#	ARTICLE	IF	CITATIONS
596	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2006, 48, e149-e246.	1.2	312
597	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing) Tj ETQq1 1 0.784314rgBT /Overlock 10 Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. European Heart Journal, 2006, 27, 1473-1483.	0.7	661
598	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	1.0	1,144
599	How Can We Improve Our Use of Oral Anticoagulants?. American Journal of Medicine, 2006, 119, 101-102.	0.6	5
600	Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. Journal of Clinical Neuroscience, 2006, 13, 823-827.	0.8	149
601	Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis. Thrombosis Research, 2006, 118, 321-333.	0.8	219
602	Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. The Cochrane Library, 2006, , CD001938.	1.5	26
604	Recent Developments in Antithrombotic Therapy: Will Sodium Warfarin Be a Drug of the Past?. Recent Patents on Cardiovascular Drug Discovery, 2006, 1, 307-316.	1.5	10
607	Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study. Journal of Thrombosis and Thrombolysis, 2006, 21, 73-77.	1.0	111
608	Effect of Study Setting on Anticoagulation Control. Chest, 2006, 129, 1155-1166.	0.4	453
609	Mixed Comparison of Stroke Prevention Treatments in Individuals With Nonrheumatic Atrial Fibrillation. Archives of Internal Medicine, 2006, 166, 1269.	4.3	139
610	Seasonal Variation in Stroke and Stroke-Associated Mortality in Patients with a Hospital Diagnosis of Nonvalvular Atrial Fibrillation or Flutter. Neuroepidemiology, 2006, 26, 220-225.	1.1	24
611	Trends in Risk of Stroke in Patients with a Hospital Diagnosis of Nonvalvular Atrial Fibrillation: National Cohort Study in Denmark, 1980-2002. Neuroepidemiology, 2006, 26, 212-219.	1.1	32
612	Optimising stroke prevention in non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy, 2006, 7, 2079-2094.	0.9	4
613	Stroke prophylaxis in atrial fibrillation: who gets it and who does not?. European Heart Journal, 2006, 27, 1954-1964.	1.0	173
614	Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. European Heart Journal, 2006, 27, 2217-2223.	1.0	60
615	Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart, 2006, 92, 1064-1070.	1.2	143
616	Atrial Fibrillation and Stroke: From Scientific Evidence to Practice. Clinical and Experimental Hypertension, 2006, 28, 251-257.	0.5	4

#	ARTICLE	IF	CITATIONS
617	Effect of oxolamine on anticoagulant effect of warfarin. American Journal of Health-System Pharmacy, 2006, 63, 153-156.	0.5	6
618	Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart, 2006, 92, 196-200.	1.2	39
619	Outcome of Vineberg's operation after 31 years. Heart, 2006, 92, 1070-1070.	1.2	3
620	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillationâ€”Executive Summary. Circulation, 2006, 114, 700-752.	1.6	294
621	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationâ€”executive summary. European Heart Journal, 2006, 27, 1979-2030.	1.0	612
622	Brain Embolism. , 0, , .		11
623	Bringing the Benefits of Anticoagulation Management Services to the Community. Canadian Pharmacists Journal, 2006, 139, 58-64.	0.4	9
624	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2006, 114, e257-354.	1.6	2,120
626	ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation. American Journal of Health-System Pharmacy, 2007, 64, 2281-2291.	0.5	4
627	Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial. Cmaj, 2007, 176, 1583-1587.	0.9	62
628	Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease. Circulation, 2007, 115, 2398-2409.	1.6	68
629	Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. Circulation, 2007, 116, 449-455.	1.6	82
630	Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. Cmaj, 2007, 176, 1589-1594.	0.9	115
631	Newly Detected Atrial Fibrillation and Compliance With Antithrombotic Guidelines. Archives of Internal Medicine, 2007, 167, 246.	4.3	149
632	Age and Risk of Stroke in Atrial Fibrillation: Evidence for Guidelines?. Neuroepidemiology, 2007, 28, 109-115.	1.1	19
634	Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace, 2007, 9, 1006-1023.	0.7	254
635	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal Supplements, 2007, 9, C3-C74.	0.0	40
636	A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age and Ageing, 2007, 36, 151-156.	0.7	259

#	ARTICLE	IF	CITATIONS
637	Racial Disparities in the Filling of Warfarin Prescriptions for Nonvalvular Atrial Fibrillation. American Journal of the Medical Sciences, 2007, 333, 67-73.	0.4	16
638	Incidence of Major Bleeding Complication of Warfarin Therapy in Japanese Patients With Atrial Fibrillation. Circulation Journal, 2007, 71, 761-765.	0.7	89
639	Trend in Mortality after Stroke with Atrial Fibrillation. American Journal of Medicine, 2007, 120, 47-53.	0.6	82
640	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Espanola De Cardiologia, 2007, 60, 525.e1-525.e64.	0.6	13
641	Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Annals of Internal Medicine, 2007, 146, 857.	2.0	3,980
642	Transient Atrial Fibrillation Complicating Acute Inferior Myocardial Infarction. Chest, 2007, 132, 44-49.	0.4	116
643	Clinical Predictors of Left Atrial Thrombus and Spontaneous Echocardiographic Contrast in Patients with Atrial Fibrillation. Journal of the American Society of Echocardiography, 2007, 20, 1181-1185.	1.2	49
644	Quelles précautions chez un patient en arythmie compliquée par fibrillation auriculaire avant une anesthésie ?. Praticien En Anesthesie Reanimation, 2007, 11, 290-300.	0.0	0
645	Anticoagulation in atrial fibrillation: A contemporary viewpoint. Heart Rhythm, 2007, 4, S34-S39.	0.3	20
646	Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. Journal of the American College of Cardiology, 2007, 50, 2156-2161.	1.2	422
648	GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. Rational Pharmacotherapy in Cardiology, 2007, 3, 88-111.	0.3	3
649	AMERICAN COLLEGE OF CARDIOLOGY, AMERICAN HEART ASSOCIATION AND EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES (2006) FOR THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION (ENDING). Rational Pharmacotherapy in Cardiology, 2007, 3, 84-111.	0.3	4
650	Atrial fibrillation: insights from clinical trials and novel treatment options. Journal of Internal Medicine, 2007, 262, 593-614.	2.7	20
651	Warfarin Therapy Initiated before Is More Beneficial Than after Transesophageal Echocardiography Detected Left Atrial Thrombus. Echocardiography, 2007, 24, 14-9.	0.3	4
652	Atrial fibrillation and stroke prevention. Lancet Neurology, The, 2007, 6, 981-993.	4.9	216
653	Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETWORK (AFNET) and the European Heart Rhythm Association (EHRA). European Heart Journal, 2007, 28, 2803-2817.	1.0	335
654	Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. Journal of Thrombosis and Thrombolysis, 2007, 23, 65-71.	1.0	32
656	Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. Journal of Thrombosis and Thrombolysis, 2008, 25, 26-32.	1.0	24

#	ARTICLE	IF	CITATIONS
657	Advancement in antithrombotics for stroke prevention in atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2008, 22, 129-137.	0.6	21
658	Application of a Decision Support Tool for Anticoagulation in Patients with Non-valvular Atrial Fibrillation. <i>Journal of General Internal Medicine</i> , 2008, 23, 411-417.	1.3	27
659	Increasing US Emergency Department Visit Rates and Subsequent Hospital Admissions for Atrial Fibrillation from 1993 to 2004. <i>Annals of Emergency Medicine</i> , 2008, 51, 58-65.	0.3	143
660	Pharmacotherapy of Atrial Fibrillation. <i>Annals of Noninvasive Electrocardiology</i> , 1998, 3, 153-161.	0.5	0
661	Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment. <i>Chest</i> , 2008, 133, 257S-298S.	0.4	655
662	Chapter 36 Cardioembolic stroke. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 93, 719-749.	1.0	3
663	Atrial fibrillation in chronic non-cardiac disease: Where do we stand?. <i>International Journal of Cardiology</i> , 2008, 128, 311-315.	0.8	58
664	Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005. <i>American Heart Journal</i> , 2008, 155, 829-840.	1.2	18
665	Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. <i>Heart</i> , 2008, 94, 1607-1613.	1.2	60
666	Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation. <i>Medical Clinics of North America</i> , 2008, 92, 143-159.	1.1	10
667	Stroke Prevention in Atrial Fibrillation and Other Major Cardiac Sources of Embolism. <i>Neurologic Clinics</i> , 2008, 26, 1129-1160.	0.8	26
668	Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature. <i>Current Medical Research and Opinion</i> , 2008, 24, 1459-1472.	0.9	37
669	Reducing the Risk for Stroke in Patients Who Have Atrial Fibrillation. <i>Cardiology Clinics</i> , 2008, 26, 267-275.	0.9	15
670	Use of dose modification schedules is effective for blinding trials of warfarin: evidence from the WASID study. <i>Clinical Trials</i> , 2008, 5, 23-30.	0.7	12
671	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. <i>Circulation</i> , 2008, 118, 2029-2037.	1.6	789
672	Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. <i>Europace</i> , 2008, 10, 395-402.	0.7	20
673	Antithrombotic Therapy in Atrial Fibrillation. <i>Chest</i> , 2008, 133, 546S-592S.	0.4	706
675	Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 84-91.	0.9	451

#	ARTICLE	IF	CITATIONS
676	Pharmacology and Management of the Vitamin K Antagonists. <i>Chest</i> , 2008, 133, 160S-198S.	0.4	1,926
677	Valvular and Structural Heart Disease. <i>Chest</i> , 2008, 133, 593S-629S.	0.4	227
679	Treatment of Atrial Fibrillation and Atrial Flutter. <i>Cardiology in Review</i> , 2008, 16, 230-239.	0.6	12
680	Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 51-55.	0.6	19
683	Who is responsible for the care of patients treated with warfarin therapy?. <i>Medical Journal of Australia</i> , 2009, 190, 674-677.	0.8	21
684	Atrial Mechanical Function after Atrial Fibrillation Ablation. , 2009, , 225-232.		0
685	How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-Valvular Atrial Fibrillation?. <i>Yonsei Medical Journal</i> , 2009, 50, 83.	0.9	14
686	Subtherapeutic oral anticoagulant therapy: Frequency and risk factors. <i>Thrombosis and Haemostasis</i> , 2009, 101, 552-556.	1.8	21
687	Cardiac Disorders and Stroke in Children and Young Adults. , 2009, , 135-159.		1
688	Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. <i>International Journal of Nephrology and Renovascular Disease</i> , 2009, 2, 33.	0.8	43
689	Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2223-2233.	3.0	400
690	Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation. <i>Stroke</i> , 2009, 40, 1410-1416.	1.0	306
691	Improving Antithrombotic Management in Patients With Atrial Fibrillation: Current Status and Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 527-542.	1.5	27
692	Use and Underuse of Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Old and New Paradigms. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 554-559.	1.5	22
693	Anticoagulant Management in Patients with Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 543-547.	1.5	1
694	The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation. <i>Circulation</i> , 2009, 120, 1029-1035.	1.6	79
695	Left Atrial Appendage Occlusion Eliminates the Need for Warfarin. <i>Circulation</i> , 2009, 120, 1919-1926.	1.6	44
696	Randomized study of surgical isolation of the pulmonary veins for correction of permanent atrial fibrillation associated with mitral valve disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 138, 454-459.	0.4	39

#	ARTICLE	IF	CITATIONS
697	Acute and Chronic Management of Atrial Fibrillation in Patients With Late-Stage CKD. <i>American Journal of Kidney Diseases</i> , 2009, 53, 701-710.	2.1	18
699	Antikoagulation bei Vorhofflimmern "Altes und Neues. <i>Clinical Research in Cardiology Supplements</i> , 2009, 4, 176-183.	2.0	1
700	Clinical consequences of hospital variation in use of oral anticoagulant therapy after first-time admission for atrial fibrillation. <i>Journal of Internal Medicine</i> , 2009, 265, 335-344.	2.7	4
701	Warfarin Is Not Needed in Low-Risk Patients Following Atrial Fibrillation Ablation Procedures. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 988-993.	0.8	71
702	Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 241-248.	0.8	341
703	Neuropsychological deficits in asymptomatic atrial fibrillation. <i>Acta Neurologica Scandinavica</i> , 1997, 96, 310-316.	1.0	54
704	Vitamin K: A Practical Guide to the Dietary Management of Patients on Warfarin. <i>Nutrition Reviews</i> , 1999, 57, 288-296.	2.6	76
705	Atrial fibrillation and coagulation: Who and when?. <i>Blood Reviews</i> , 2009, 23, 241-244.	2.8	6
706	An approach to therapy of supraventricular tachyarrhythmias: An algorithm versus individualized therapy. <i>Clinical Cardiology</i> , 2009, 17, II-21-II-26.	0.7	2
708	Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. <i>American Heart Journal</i> , 2009, 157, 805-810.e2.	1.2	298
710	Long-term Follow-up of Atrial Fibrillation Patients in the NASPEAF Study. Prospective Evaluation of Different Antiplatelet Treatments. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 992-1000.	0.4	6
711	Variability in the Prescription of Cardiovascular Medications in Older Patients. <i>Drugs and Aging</i> , 2009, 26, 41-51.	1.3	10
712	Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors. <i>Journal of Arrhythmia</i> , 2009, 25, 81-88.	0.5	0
713	Combination of clopidogrel and aspirin for reduction of vascular events in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 749-753.	0.6	1
714	Stroke prevention in atrial fibrillation: WATCHMAN versus warfarin. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 727-729.	0.6	15
715	Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. <i>Lancet, The</i> , 2009, 374, 534-542.	6.3	1,876
716	Placas de ateroma: descripción cuantitativa de la ecogenicidad por capas. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 984-991.	0.6	7
718	Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: A meta-analysis. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 916-925.	0.5	33

#	ARTICLE	IF	CITATIONS
719	Milestones in the management of atrial fibrillation. <i>Heart Rhythm</i> , 2009, 6, S62-S67.	0.3	34
720	Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation. <i>Cardiology Clinics</i> , 2009, 27, 125-135.	0.9	7
721	The current role of anticoagulants in cardiovascular medicine. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 595-604.	0.6	17
722	Measuring Quality of Oral Anticoagulation Care: Extending Quality Measurement to a New Field. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2009, 35, 146-155.	0.4	46
723	Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation. <i>Current Pharmaceutical Design</i> , 2010, 16, 3455-3471.	0.9	14
724	Randomized study of surgical isolation of the pulmonary veins for correction of permanent atrial fibrillation associated with mitral valve disease. <i>Yearbook of Cardiology</i> , 2010, 2010, 255-257.	0.0	0
725	Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1106-1115.	1.8	98
726	Evaluation of Pharmacogenetic Algorithm for Warfarin Dose Requirements in Japanese Patients. <i>Circulation Journal</i> , 2010, 74, 977-982.	0.7	28
727	Combined oral anticoagulants and antiplatelets: benefits and risks. <i>Internal and Emergency Medicine</i> , 2010, 5, 281-290.	1.0	14
728	Systemic inflammation and left atrial thrombus in patients with non-rheumatic atrial fibrillation. <i>Journal of Cardiology</i> , 2010, 56, 118-124.	0.8	27
729	Upper-Limb Thrombo-Embolectomy: National Cohort Study in Denmark. <i>European Journal of Vascular and Endovascular Surgery</i> , 2010, 40, 628-634.	0.8	25
730	Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2201-2207.	1.9	40
733	Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. <i>Patient Preference and Adherence</i> , 2010, 4, 51.	0.8	103
734	Relationship Between CHADS2 Score and Ischemic Stroke During Rhythm Control Therapy for Paroxysmal Atrial Fibrillation. <i>International Heart Journal</i> , 2010, 51, 24-29.	0.5	12
735	Long-Term Oral Anticoagulation Therapy and the Risk of Hip Fracture in Patients with Previous Hemispheric Infarction and Nonrheumatic Atrial Fibrillation. <i>Cerebrovascular Diseases</i> , 2010, 29, 73-78.	0.8	28
737	Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2010, 170, 1433-41.	4.3	727
738	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010, 31, 2133-2140.	1.0	35
739	Self-monitoring and self-management of oral anticoagulation. , 2010, , CD003839.		86

#	ARTICLE	IF	CITATIONS
740	Recent advances in oral anticoagulation for atrial fibrillation. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 395-407.	1.0	5
741	Left Atrial Volume Combined With Atrial Pump Function Identifies Hypertensive Patients With a History of Paroxysmal Atrial Fibrillation. Hypertension, 2010, 55, 1150-1156.	1.3	69
743	Stroke prevention in atrial fibrillation patients. Expert Opinion on Pharmacotherapy, 2010, 11, 2331-2350.	0.9	5
744	Principles of Anticoagulation and New Therapeutic Agents in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2010, 2, 479-492.	0.7	1
745	Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: A reappraisal of the evidence and network meta analysis. International Journal of Cardiology, 2010, 142, 218-223.	0.8	12
746	Predictors of Warfarin Use in Atrial Fibrillation Patients in the Inpatient Setting. American Journal of Cardiovascular Drugs, 2010, 10, 37-48.	1.0	42
747	Hemorrhagic and Thrombotic Events Associated with Generic Substitution of Warfarin in Patients with Atrial Fibrillation: A Retrospective Analysis. Annals of Pharmacotherapy, 2011, 45, 701-712.	0.9	23
748	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 57, e101-e198.	1.2	756
749	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq0 0.0 rgBT /Overlock 10	1.2	262
750	Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 57, 1339-1348.	1.2	191
752	Antithrombotic therapy in nonvalvular atrial fibrillation: A narrative review. Revista Portuguesa De Cardiologia, 2011, 30, 905-924.	0.2	4
753	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq1 1 0.784314 rgBT /Ov	0.3	114
754	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter. Canadian Journal of Cardiology, 2011, 27, 74-90.	0.8	273
755	Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.8	26
757	Neurology and Cardiology: Points of Contact. Revista Espanola De Cardiologia (English Ed ), 2011, 64, 319-327.	0.4	4
758	Antithrombotic therapy in nonvalvular atrial fibrillation: A narrative review. Revista Portuguesa De Cardiologia (English Edition), 2011, 30, 905-924.	0.2	3
759	All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation. Journal of Managed Care Pharmacy, 2011, 17, 672-684.	2.2	65
761	Current and emerging therapies for stroke prophylaxis in atrial fibrillation. Clinical Investigation, 2011, 1, 1019-1037.	0.0	0



#	ARTICLE	IF	CITATIONS
762	Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, 1.	2.0	363
763	Cerebral microbleeds and antithrombotic treatment. , 0, , 165-172.		0
764	Atrial fibrillation and upper limb thromboembolism: a national cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1738-1743.	1.9	14
765	Atrial Fibrillation in Chronic Hemodialysis Patients: Prevalence, Types, Predictors, and Treatment Practices in Greece. <i>Artificial Organs</i> , 2011, 35, 916-922.	1.0	22
766	Patient Safety in Primary Care: Are General Practice Nurses the Answer to Improving Warfarin Safety? An Australian Perspective. <i>Worldviews on Evidence-Based Nursing</i> , 2011, 8, 25-29.	1.2	1
767	The Society of Thoracic Surgeons Practice Guideline on the Prophylaxis and Management of Atrial Fibrillation Associated With General Thoracic Surgery: Executive Summary. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1144-1152.	0.7	109
768	Prevalence and Predictors of Warfarin Use in Patients With Atrial Fibrillation at Low or Intermediate Risk and Relation to Thromboembolic Events. <i>Clinical Cardiology</i> , 2011, 34, 640-644.	0.7	8
769	Dabigatran in atrial fibrillation: pharmacology and clinical trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2011, 32, 173-180.	0.6	7
770	Stroke Prevention in Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 561-570.	1.3	4
771	Prevention of Cardioembolic Stroke. <i>Neurotherapeutics</i> , 2011, 8, 488-502.	2.1	31
772	Stroke Prevention Treatment of Patients with Atrial Fibrillation: Old and New. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 15-27.	2.0	0
773	Risk modeling strategies for pharmacogenetic studies. <i>Pharmacogenomics</i> , 2011, 12, 397-410.	0.6	1
774	The Business Case for Quality Improvement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 416-424.	0.9	45
775	Pharmacological Management of Atrial Fibrillation: One, None, One Hundred Thousand. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-10.	0.5	2
776	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq0 0.0 rgBT /Overlock 10 1.6 618	1.6	618
777	Achieving target international normalization ratio in haemodialysis patients with atrial fibrillation: is it feasible?. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 279-279.	1.4	0
778	The Role of Apixaban for Venous and Arterial Thromboembolic Disease. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1262-1283.	0.9	16
779	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, e269-367.	1.6	747

#	ARTICLE	IF	CITATIONS
780	Effect of prophylactic amiodarone in patients with rheumatic valve disease undergoing valve replacement surgery. <i>Annals of Cardiac Anaesthesia</i> , 2011, 14, 176.	0.3	15
781	Antiplatelet Therapy in Stroke Prevention. <i>Advances in Cardiology</i> , 2012, 47, 141-154.	2.6	7
782	Newer Anticoagulants in Cardiovascular Disease. <i>Cardiology in Review</i> , 2012, 20, 209-221.	0.6	24
783	Stroke Prevention in Atrial Fibrillation: Where are We Now?. <i>Clinical Medicine Insights: Cardiology</i> , 2012, 6, CMC.S8976.	0.6	9
784	Preventing stroke in atrial fibrillation patients &ndash; clinical utility of oral anticoagulants. <i>Journal of Blood Medicine</i> , 2012, 3, 1.	0.7	0
785	Novel anticoagulants in atrial fibrillation stroke prevention. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 123-136.	1.1	16
786	Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2012, 43, 881-883.	1.0	92
787	Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. <i>Current Cardiology Reviews</i> , 2012, 8, 290-301.	0.6	12
788	Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features. <i>Current Cardiology Reviews</i> , 2012, 8, 281-289.	0.6	25
789	Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke. <i>Current Pharmaceutical Design</i> , 2012, 18, 5261-5272.	0.9	7
791	Stroke prevention in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 73-85.	0.6	11
794	Forty Years in Academic Cardiology. <i>Cardiology in Review</i> , 2012, 20, 265-267.	0.6	0
795	Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 433-439.	0.6	7
796	Data and Safety Monitoring. , 2012, , 101-108.		1
797	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. <i>Thrombosis Research</i> , 2012, 129, 392-400.	0.8	56
798	Relation of Gender-Specific Risk of Ischemic Stroke in Patients With Atrial Fibrillation to Differences in Warfarin Anticoagulation Control (from AFFIRM). <i>American Journal of Cardiology</i> , 2012, 110, 1799-1802.	0.7	85
799	Assessment of Advantages and Disadvantages of Agents Used For Therapeutic Anticoagulation. <i>Disease-a-Month</i> , 2012, 58, 462-468.	0.4	0
800	Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2012, 172, 623.	4.3	139

#	ARTICLE	IF	CITATIONS
801	Atrial Fibrillation Management in Elderly. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 431-442.	0.8	1
802	Left Atrial Strain Is Reduced in Patients with Atrial Fibrillation, Stroke or TIA, and Low Risk CHADS2 Scores. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 1327-1332.	1.2	79
804	Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e44064.	1.1	142
805	Oral Anticoagulant Therapy. <i>Chest</i> , 2012, 141, e44S-e88S.	0.4	1,323
806	Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 2298-2307.	1.6	418
807	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2012, 141, e531S-e575S.	0.4	891
808	Proportion of Patients with Implanted Permanent Pacemakers with Atrial Fibrillation Receiving Appropriate Medical Prophylaxis in North Wales. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 935-942.	0.5	1
809	Relationship between CHA2DS2-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation without receiving anticoagulant therapy. <i>Journal of Cardiology</i> , 2012, 59, 321-328.	0.8	20
810	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. <i>American Journal of Hematology</i> , 2012, 87, S100-7.	2.0	5
811	Promise of Factor Xa Inhibition in Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2012, 14, 70-78.	1.3	3
812	Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment. <i>Neurocritical Care</i> , 2012, 16, 203-209.	1.2	32
813	Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 88-97.	1.0	16
814	Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation. <i>Journal of Medical Economics</i> , 2013, 16, 1193-1202.	1.0	11
815	Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 367-375.	2.3	25
816	Gender and the risk of stroke in atrial fibrillation: impact of old and new anticoagulation regimens. <i>Clinical Research in Cardiology Supplements</i> , 2013, 8, 38-45.	2.0	1
817	Handbook of Oral Anticoagulation. , 2013, , .		1
818	Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 836-844.	1.9	26
819	Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease. <i>Annals of Medicine</i> , 2013, 45, 274-290.	1.5	25

#	ARTICLE	IF	CITATIONS
820	Blood pressure. The forgotten factor in previous and recent studies regarding anticoagulation in atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 4434-4435.	0.8	5
822	Evaluaci3n de riesgo tromboemb3lico y hemorr3gico de los pacientes con fibrilaci3n auricular. <i>Revista Espanola De Cardiologia Suplementos</i> , 2013, 13, 9-13.	0.2	6
823	Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice. <i>Postgraduate Medical Journal</i> , 2013, 89, 346-351.	0.9	7
824	Review of epidemiology and management of atrial fibrillation in developing countries. <i>International Journal of Cardiology</i> , 2013, 167, 2412-2420.	0.8	106
825	Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly. <i>Drugs and Aging</i> , 2013, 30, 513-525.	1.3	16
826	Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients. <i>Current Medical Research and Opinion</i> , 2013, 29, 1253-1261.	0.9	9
827	Stroke Stop Study: editorial comment. <i>Europace</i> , 2013, 15, 5-6.	0.7	4
828	Alternatives to Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Look Back at the State of the Field in 2012. <i>Postgraduate Medicine</i> , 2013, 125, 146-157.	0.9	0
829	Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus Warfarin. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 567-574.	0.9	131
830	The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. <i>Journal of Hypertension</i> , 2013, 31, 2109-2117.	0.3	19
831	Rates of hemorrhage during warfarin therapy for atrial fibrillation. <i>Cmaj</i> , 2013, 185, E121-E127.	0.9	159
832	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 2192-2201.	1.6	268
834	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
835	Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence. <i>Vascular Health and Risk Management</i> , 2013, 9, 3.	1.0	16
836	ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 292-300.	0.3	0
837	Effectiveness of Pharmacy Run Anticoagulation Clinics Compared to Large Clinical Trials of New Oral Anticoagulants. <i>Journal of Pharmaceutical Care &amp; Health Systems</i> , 2014, 1, .	0.1	0
838	THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER. <i>Rational Pharmacotherapy in Cardiology</i> , 2014, 10, 625-630.	0.3	7
839	Comparison Between CHADS2 and CHA2DS2-VASc Score for Risk Stratification of Ischemic Stroke in Japanese Patients With Non-Valvular Paroxysmal Atrial Fibrillation Not Receiving Anticoagulant Therapy. <i>International Heart Journal</i> , 2014, 55, 119-125.	0.5	19

#	ARTICLE	IF	CITATIONS
840	Neurologic Manifestations of Acquired Cardiac Disease, Arrhythmias, and Interventional Cardiology. , 2014, , 79-97.		0
841	Benefitâ€“risk assessment in a postâ€“market setting: a case study integrating realâ€“life experience into benefitâ€“risk methodology. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 974-983.	0.9	17
842	Incidence, Mortality, and Risk Factors for Oral Anticoagulantâ€“associated Intracranial Hemorrhage in Patients with Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 2479-2488.	0.7	22
843	Impact of Structural Heart Disease on the Acute Complication Rate in Atrial Fibrillation Ablation: Results from the German Ablation Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 242-249.	0.8	22
844	Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 21-37.	1.0	13
845	Stroke Risk in Patients with Implanted Cardiac Devices. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 133-139.	0.7	0
846	Costâ€“Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 87-98.	1.3	18
847	Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79â€“...808 patients. <i>Heart</i> , 2014, 100, 396-405.	1.2	58
848	Atrial Fibrillation and Stroke. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 31-41.	0.7	2
849	Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. <i>European Heart Journal</i> , 2014, 35, 1881-1887.	1.0	96
850	Antithrombotic Therapy After Acute Ischemic Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 3637-3642.	1.0	19
851	Anticoagulation Strategies for the Management of Postoperative Atrial Fibrillation. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 537-561.	0.7	31
852	Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. <i>Journal of Medical Economics</i> , 2014, 17, 771-781.	1.0	13
853	Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 226-234.	1.0	6
854	Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. <i>Thrombosis Journal</i> , 2014, 12, 14.	0.9	86
855	Left Atrial Appendage Exclusion for Prevention of Stroke in Atrial Fibrillation: Review of Minimally Invasive Approaches. <i>Current Cardiology Reports</i> , 2014, 16, 448.	1.3	15
856	Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1-12.	1.2	1,605
857	Drug Therapies for Stroke Prevention in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 61-78.	0.7	0

#	ARTICLE	IF	CITATIONS
858	Stroke and Bleeding Risks in Patients with Atrial Fibrillation. <i>Interventional Cardiology Clinics</i> , 2014, 3, 175-190.	0.2	0
859	Safety of acupuncture treatments for patients taking warfarin or antiplatelet medications: Retrospective chart review study. <i>European Journal of Integrative Medicine</i> , 2014, 6, 492-496.	0.8	11
860	Atrial fibrillation: Stroke prevention in focus. <i>Australian Critical Care</i> , 2014, 27, 92-98.	0.6	18
861	Vitamin K for improved anticoagulation control in patients receiving warfarin. <i>The Cochrane Library</i> , 2014, , CD009917.	1.5	4
862	Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity-Matched Analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1310-1316.	0.5	6
863	Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc $\geq 1$ , or higher?. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1165-1169.	1.8	52
864	Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. <i>BMJ, The</i> , 2015, 351, h3786.	3.0	54
865	Percutaneous left atrial appendage closure: a review of the WATCHMAN clinical trial experience. <i>Interventional Cardiology</i> , 2015, 7, 333-344.	0.0	0
866	A novel approach indirectly comparing benefit-risk balance across anti-thrombotic therapies in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 15-28.	1.4	15
868	Cardiogenic embolism in the cat. <i>Journal of Veterinary Cardiology</i> , 2015, 17, S202-S214.	0.3	11
869	Device-Detected Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 281-294.	1.2	52
870	Poor adherence to anticoagulation guidelines in patients with non-valvular atrial fibrillation treated in a tertiary cardiology unit. <i>Heart Asia</i> , 2015, 7, 18-22.	1.1	10
871	Management of anticoagulation in patients with acute gastrointestinal bleeding. <i>Digestive and Liver Disease</i> , 2015, 47, 621-627.	0.4	58
872	Editorial comment on "A novel approach indirectly comparing benefit-risk across oral antithrombotic therapies in patients with atrial fibrillation". Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 83-85.	1.4	1
873	Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 182-190.	1.9	28
874	Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2728-2739.	1.2	86
875	Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 1103.e1-1103.e19.	1.2	40
876	Bleeding risk, physical functioning and non-use of anticoagulation among patients with stroke and atrial fibrillation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 189-196.	0.2	1

#	ARTICLE	IF	CITATIONS
878	Treatment and Prevention of Feline Arterial Thromboembolism. , 2016, , 369-378.		1
879	Primary prevention of cardiovascular disease. Tenri Medical Bulletin, 2016, 19, 90-94.	0.1	0
881	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 93-107.	0.8	35
882	Developing alerting thresholds for prospective drug safety monitoring. Pharmacoepidemiology and Drug Safety, 2016, 25, 755-762.	0.9	0
884	Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. Journal of the American Heart Association, 2016, 5, .	1.6	55
885	Self-monitoring and self-management of oral anticoagulation. The Cochrane Library, 2021, 2021, CD003839.	1.5	92
886	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	17
887	Secondary Prevention After Cardioembolic Stroke. , 2016, , 111-135.		1
888	Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 5-19.	0.7	9
889	Absence of left atrial stunning after cardioversion of recent-onset atrial fibrillation in patients at low-stroke risk. European Journal of Emergency Medicine, 2017, 24, 217-223.	0.5	2
890	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation. JAMA Cardiology, 2017, 2, 324.	3.0	28
891	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. Journal of the American Heart Association, 2017, 6, .	1.6	8
892	Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report. American Journal of Kidney Diseases, 2017, 70, 859-868.	2.1	25
893	Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study. European Journal of Clinical Pharmacology, 2017, 73, 1681-1689.	0.8	3
894	Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis. Journal of Zhejiang University: Science B, 2017, 18, 567-576.	1.3	18
895	Interventional and surgical occlusion of the left atrial appendage. Nature Reviews Cardiology, 2017, 14, 727-743.	6.1	35
896	Percutaneous Left Atrial Appendage Closure With the LAMBE Device for Stroke Prevention in Atrial Fibrillation. JACC: Cardiovascular Interventions, 2017, 10, 2188-2194.	1.1	85
897	Feline Cardiogenic Arterial Thromboembolism. Veterinary Clinics of North America - Small Animal Practice, 2017, 47, 1065-1082.	0.5	23

#	ARTICLE	IF	CITATIONS
898	Atrial fibrillation in women: treatment. <i>Nature Reviews Cardiology</i> , 2017, 14, 113-124.	6.1	56
899	Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 208-219.	1.6	103
901	Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 42.	1.1	1
902	Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 443.	0.7	24
903	Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 175-181.	0.6	6
904	Clinical Trials for Atrial Fibrillation—What Do We Know?. , 2018, , 630-642.		0
905	New developments in clinical ischemic stroke prevention and treatment and their imaging implications. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1533-1550.	2.4	10
906	Clinical manifestations and outcomes of severe warfarin overanticoagulation: from the EWA study. <i>Annals of Medicine</i> , 2018, 50, 164-171.	1.5	0
907	The Impact of Comorbidity on Rehabilitation Outcome After Ischemic Stroke. <i>Acta Clinica Croatica</i> , 2018, 57, 5-15.	0.1	30
908	Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study. <i>Current Medical Research and Opinion</i> , 2018, 34, 2157-2164.	0.9	8
909	Screening for Atrial Fibrillation With Electrocardiography. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 485.	3.8	94
910	Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2018, 49, 1464-1470.	1.0	32
911	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.4	718
912	Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 499-508.	1.0	2
913	Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data. <i>Journal of the American Heart Association</i> , 2019, 8, e011577.	1.6	32
914	Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 481-488.	1.3	11
916	Left atrial appendage strain rate is associated with documented thromboembolism in nonvalvular atrial fibrillation. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 156-164.	1.0	13
917	Implication of Preoperative Existence of Atrial Fibrillation on Hemocompatibility-Related Adverse Events During Left Ventricular Assist Device Support. <i>Circulation Journal</i> , 2019, 83, 1286-1292.	0.7	8



#	ARTICLE	IF	CITATIONS
918	Letter to the Editor concerning: "A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants". International Journal of Cardiology, 2019, 297, 66.	0.8	1
919	Anticoagulation Drug Trials for Stroke Prevention in Atrial Fibrillation. , 2019, , 35-46.		1
920	Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation. Stroke, 2020, 51, 2364-2373.	1.0	33
921	Knowledge, Adherence, and Quality of Life among Warfarin Therapy Users. , 0, , .		0
922	Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation. JAMA Network Open, 2020, 3, e1919396.	2.8	76
923	Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Scientific Reports, 2020, 10, 662.	1.6	16
924	Minor bleeding affects the level of knowledge in patients with atrial fibrillation on oral anticoagulant therapy. International Journal of Clinical Practice, 2020, 74, e13483.	0.8	3
925	Time to Deprescribe: A Time-Centric Model for Deprescribing at End of Life. Journal of Palliative Medicine, 2021, 24, 273-284.	0.6	5
926	Non-Vitamin K Antagonist Oral Anticoagulant vs Warfarin for Post Cardiac Surgery Atrial Fibrillation. Annals of Thoracic Surgery, 2021, 112, 1392-1401.	0.7	18
927	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. European Heart Journal, 2022, 43, 940-958.	1.0	8
929	Comparative risk for intracranial hemorrhage related to new oral anticoagulants. Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	1
930	Machine Learning Methodologies for Prediction of Rhythm-Control Strategy in Patients Diagnosed With Atrial Fibrillation: Observational, Retrospective, Case-Control Study. JMIR Medical Informatics, 2021, 9, e29225.	1.3	5
931	Atrial Fibrillation and Ischemic Stroke: A Clinical Review. Seminars in Neurology, 2021, 41, 348-364.	0.5	37
932	Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. Seminars in Neurology, 2021, 41, 365-387.	0.5	2
933	Natural Coumarins: Exploring the Pharmacological Complexity and Underlying Molecular Mechanisms. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-19.	1.9	59
934	Association of Oral Anticoagulation With Stroke in Atrial Fibrillation or Heart Failure. Stroke, 2021, 52, 3151-3162.	1.0	2
936	Lessons From Warfarin Trials in Atrial Fibrillation: Missing the Window of Opportunity. , 2006, , 312-319.		5
937	Guidelines for Competitive Athletes with Arrhythmias. Developments in Cardiovascular Medicine, 2000, , 119-151.	0.1	4

#	ARTICLE	IF	CITATIONS
938	The Level of Activity of the Hemostatic System, the Rate of Embolic Stroke, and Age: Is There a Correlation?. , 1995, , 437-442.		5
939	Hematologic Causes of Intracerebral Hemorrhage and Their Treatment. Neurosurgery Clinics of North America, 1992, 3, 637-658.	0.8	35
940	Review of antithrombotic drug usage in atrial fibrillation. Journal of Clinical Pharmacy and Therapeutics, 1998, 23, 97-106.	0.7	17
941	Vitamin K: A Practical Guide to the Dietary Management of Patients on Warfarin. Nutrition in Clinical Care: an Official Publication of Tufts University, 1998, 1, 117-125.	0.2	3
942	Arrhythmia issues in patients with renal disease. Seminars in Nephrology, 2001, 21, 57-65.	0.6	19
943	Orgaran (Org 10172) or Heparin for Preventing Venous Thrombosis after Elective Surgery for Malignant Disease? A Double-Blind, Randomised, Multicentre Comparison. Thrombosis and Haemostasis, 1993, 70, 562-567.	1.8	55
944	Cerebrovascular ultrasound. Current Opinion in Neurology, 1999, 12, 57-63.	1.8	12
945	Stroke in Atrial Fibrillation: A Need for Effective Anticoagulation. Southern Medical Journal, 2004, 97, 919-920.	0.3	1
947	Recent Advances: Cardiology II: Treatment of heart failure and atrial fibrillation and arrhythmias. BMJ: British Medical Journal, 1994, 309, 1631-1635.	2.4	8
948	Evidence based medicine: an approach to clinical problem-solving. BMJ: British Medical Journal, 1995, 310, 1122-1126.	2.4	917
949	How To Do It: Service provision and use of anticoagulants in atrial fibrillation. BMJ: British Medical Journal, 1995, 311, 558-560.	2.4	60
950	How To Do It: Commentary: Caution needed in introducing warfarin treatment. BMJ: British Medical Journal, 1995, 311, 560-561.	2.4	8
951	Prevention of neurological disease in later life. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 39S-52S.	0.9	6
952	Implementation of antithrombotic management in atrial fibrillation. Postgraduate Medical Journal, 2000, 76, 783-786.	0.9	11
953	Management of Deep Vein Thrombosis and Pulmonary Embolism. Circulation, 1996, 93, 2212-2245.	1.6	553
954	Thromboembolism Prophylaxis in Chronic Atrial Fibrillation. Stroke, 1997, 28, 72-76.	1.0	93
955	Warfarin Use Among Patients With Atrial Fibrillation. Stroke, 1997, 28, 2382-2389.	1.0	198
956	Long-term Oral Anticoagulation Reduces Bone Mass in Patients with Previous Hemispheric Infarction and Nonrheumatic Atrial Fibrillation. Stroke, 1997, 28, 2390-2394.	1.0	55

#	ARTICLE	IF	CITATIONS
957	Effect of treatment with low-dose warfarin-aspirin on activated factor VII. <i>Blood</i> , 1995, 85, 3034-3039.	0.6	19
958	Brain Embolism. , 1999, , 35-185.		5
959	Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants. <i>PLoS ONE</i> , 2014, 9, e88131.	1.1	11
960	Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons. <i>PLoS ONE</i> , 2014, 9, e100478.	1.1	24
961	Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect. <i>PLoS ONE</i> , 2016, 11, e0161864.	1.1	7
962	Tailored Anticoagulation for Thromboembolic Risk Reduction in Paroxysmal Atrial Fibrillation. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2018, 9, 3116-3125.	0.2	3
963	Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2017, 21, 1-386.	1.3	117
964	Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation. <i>Experimental and Therapeutic Medicine</i> , 2013, 6, 413-418.	0.8	3
965	Evolution of Left Atrial Thrombus with Anticoagulant Therapy-Follow-up by Transesophageal Echocardiography. <i>Korean Journal of Internal Medicine</i> , 1995, 10, 143-145.	0.7	3
966	Moving Beyond Warfarin—Are We Ready?: A Review of the Efficacy and Safety of Novel Anticoagulant Agents Compared to Warfarin for the Management of Atrial Fibrillation in Older Adults. <i>Journal of Gerontological Nursing</i> , 2013, 39, 8-17.	0.3	4
967	International Normalized Ratio for the monitoring of warfarin therapy. Need for standardization of the International Sensitivity Index.. <i>Nosotchu</i> , 1996, 18, 124-129.	0.0	3
968	Stroke in patients with chronic non-valvular atrial fibrillation: Effects of antiplatelet and anticoagulation therapy.. <i>Nosotchu</i> , 1997, 19, 355-360.	0.0	2
969	Atrial Fibrillation: The New Epidemic of the Ageing World. <i>Journal of Atrial Fibrillation</i> , 2009, 1, 154.	0.5	21
970	Impact of Anticoagulation Intensity in Korean Patients with Atrial Fibrillation: Is It Different from Western Population?. <i>Korean Circulation Journal</i> , 2020, 50, 163.	0.7	6
971	Clinicians-related determinants of anticoagulation therapy and prophylaxis in Nigeria. <i>Annals of African Medicine</i> , 2017, 16, 164.	0.2	3
972	Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Cardiovascular Medicine(Switzerland)</i> , 2013, 16, 103-114.	0.1	7
973	Prevalence of cerebral infarction in patients with atrial fibrillation.. <i>Japanese Journal of Electrocardiology</i> , 1999, 19, 12-19.	0.0	2
974	Management and comorbidities of atrial fibrillation in patients admitted in cardiology service in Kosovo-a single-center study. <i>Anatolian Journal of Cardiology</i> , 2010, 10, 36-40.	0.4	16

#	ARTICLE	IF	CITATIONS
975	Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 111-134.	0.3	4
976	Prevalence of oral anticoagulation in atrial fibrillation. Clinics, 2014, 69, 615-620.	0.6	14
977	Therapeutic Options for Established or Recurrent Atrial Fibrillation: Focus on Antithrombotic Therapy. Developments in Cardiovascular Medicine, 2000, , 133-139.	0.1	0
978	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology American Society of Hematology Education Program, 2000, 2000, 266-284.	0.9	2
979	Antikoagulation – Indikation, Durchführung, klinische Ergebnisse. , 2000, , 79-91.		0
980	Schlaganfallbehandlung – medikamentöse Behandlung des Schlaganfalls. , 2000, , 69-84.		0
982	Epidemiologie, klinischer Verlauf und Prognose. , 2000, , 3-20.		0
983	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology American Society of Hematology Education Program, 2000, 2000, 266-284.	0.9	0
984	Antithrombotic therapy in atrial fibrillation. , 2000, , 195-225.		0
985	Cerebrovascular Disease: Experience Within Large Multicentre Trials. , 2001, , 229-249.		0
986	Anticoagulation with warfarin for primary prevention of ischemic stroke in patients with nonvalvular atrial fibrillation.. Nosotchu, 2001, 23, 188-194.	0.0	0
987	Clinical Trials in Stroke Prevention in North America. , 2001, , 213-228.		0
988	Self-management of Oral Anticoagulants by Patients with Atrial Fibrillation: How Effective and Safe Is It?. , 2002, , 436-440.		0
989	Data and Safety Monitoring Boards. , 2002, , 63-68.		6
990	Antiplatelet Agents for Prevention of Thromboembolism in Atrial Fibrillation: When, Why, and Which One?. , 2002, , 422-435.		2
991	Evidence Based Cardiology Second Edition. Journal of the Royal Naval Medical Service, 2002, 88, 131.1-131.	0.0	1
992	Prognosis After Stroke. , 2002, , .		0
996	Anticoagulant and Antiplatelet Drug Therapy in Atrial Fibrillation. , 2004, , 175-186.		0

#	ARTICLE	IF	CITATIONS
997	Use of Chronic Anticoagulation in the Elderly: A Review of the Benefits and Risks. <i>Developments in Cardiovascular Medicine</i> , 2004, , 181-199.	0.1	0
998	Cardiac Embolism. , 2004, , 187-198.		0
999	Antikogulation bei Herzerkrankungen. , 2004, , 869-896.		0
1000	Complications of Atrial Fibrillation Ablation: How to Prevent and Manage Cerebrovascular Accidents. , 2006, , 231-239.		0
1001	Prevention and Management of Thromboembolism. , 2006, , 331-345.		0
1002	Antithrombotic Approaches in Cerebrovascular Disease. , 2006, , 449-466.		0
1003	Atrial Arrhythmia. <i>Fundamental and Clinical Cardiology</i> , 2006, , 167-182.	0.0	0
1004	Anticoagulation and Antiplatelet Agents. <i>Fundamental and Clinical Cardiology</i> , 2006, , 501-524.	0.0	0
1005	Cardiac disorders. , 2007, , 399-428.		0
1006	Data and Safety Monitoring Boards. , 2007, , 59-65.		0
1007	The Role of Echocardiography in Atrial Fibrillation and Flutter. , 2007, , 999-1018.		0
1009	Supraventricular Tachyarrhythmias in the Elderly. <i>Fundamental and Clinical Cardiology</i> , 2008, , 577-604.	0.0	0
1010	Antithrombotic Therapy for Atrial Fibrillation and Cardioversion. , 2010, , 389-403.		0
1011	Common clinical indications for anticoagulation. , 2010, , 7-25.		0
1013	Pharmacologic Management of Atrial Fibrillation and Flutter. , 2011, , 165-193.		0
1014	History of Supraventricular Tachycardia. , 2011, , 17-38.		0
1015	Incidence Rate and Risk Factors of Bleeding Associated with Warfarin Therapy in Elderly Atrial Fibrillation Patients. <i>Journal of Korean Society of Health-System Pharmacists</i> , 2011, 28, 1-11.	0.1	0
1021	Lowering the Risk for Thrombus and Stroke in Atrial Fibrillation Patients: Will Dabigatran Replace Warfarin?. <i>Clinical Medicine Reviews in Vascular Health</i> , 2013, 5, 1-8.	3.0	0

#	ARTICLE	IF	CITATIONS
1022	Comparison between CHADS2 and CHA2DS2-VASc Score for the Risk Stratification of Ischemic Stroke in Japanese Patients with Nonvalvular Paroxysmal Atrial Fibrillation. Japanese Journal of Electrocardiology, 2013, 33, 40-48.	0.0	0
1024	Common Clinical Indications for Anticoagulation. , 2013, , 7-31.		0
1025	Value of Left Atrial Appendage Flow Velocities in Patients with Nonrheumatic Atrial Fibrillation and Systemic Embolism. Developments in Cardiovascular Medicine, 1992, , 259-269.	0.1	0
1026	Risk and Prevention of Embolism in Atrial Fibrillation. Developments in Cardiovascular Medicine, 1992, , 237-257.	0.1	0
1027	Thromboembolism in Nonrheumatic Atrial Fibrillation: What Have We Learned?. , 1992, , 83-86.		2
1028	The Role of Ticlopidine in Prevention of Ischemic Stroke: A Benefit-Risk Assessment. , 1993, , 141-155.		1
1029	Gerinnungshemmende Behandlung des chronischen Vorhofflimmerns. , 1994, , 89-97.		0
1030	Pathogenesis and Therapy of Thrombosis in Patients with Congestive Heart Failure. , 1994, , 687-700.		2
1031	Elektrische Therapie von Vorhofflimmern und Vorhofflattern. , 1994, , 69-86.		0
1032	Oral Anticoagulant Therapy. Japanese Journal of Thrombosis and Hemostasis, 1994, 5, 114-120.	0.1	0
1033	Embolierisiko bei Vorhofflimmern â€” Indikation zur Antikoagulation bzw. Hemmung der Thrombozytenaggregation. , 1994, , 43-52.		0
1034	Thromboembolism in atrial fibrillation.. Japanese Journal of Electrocardiology, 1994, 14, 78-83.	0.0	0
1035	Anticoagulation in patients with atrial fibrillation. BMJ: British Medical Journal, 1994, 308, 653-653.	2.4	2
1036	<a href="#">Preventing Stroke in Atrial Fibrillation: Overview of the Randomized Trials of Antithrombotic Therapy</a> **Some of the material presented in this chapter appeared in earlier versions in previous publications by the author. These include Singer et al. Preventing stroke in atrial fibrillation. Coronary Artery Disease 1992;3:753â€”760 (in particular table 3); and Singer. Overview of the randomized trials to prevent stroke in atrial fibrillation. Ann Epidemiology 1993;3:563â€”567. Permission to reprint relevant materia. , 1995, , 427-436.		1
1037	Hemostatic molecular markers and left atrial diameter in nonvalvular atrial fibrillation.. Nosotchu, 1995, 17, 425-430.	0.0	0
1038	Antikoagulation und Aggregationshemmung bei Herzerkrankungen. , 1996, , 1301-1339.		0
1039	Anticoagulation in Atrial Fibrillation: Is Aspirin Sufficient?. , 1996, , 216-220.		0
1040	Managing paroxysmal atrial tachycardias in patients with pacemakers. Developments in Cardiovascular Medicine, 1996, , 167-173.	0.1	0

#	ARTICLE	IF	CITATIONS
1041	Thromboembolic Risk in Patients with Atrial Fibrillation: Can It Be Predicted on the Basis of Clinical Variables?. , 1996, , 207-211.		0
1042	The causes and management of atrial fibrillation. Journal of Clinical Pharmacy and Therapeutics, 1996, 21, 37-43.	0.7	0
1043	Primär- und Sekundärprävention des Schlaganfalls. , 1997, , 73-84.		0
1045	Clinical Aspects of Stroke and Therapeutic Strategies. , 1997, , 43-66.		0
1046	Prophylaxe ischämischer Insulte. , 1998, , 1328-1333.		0
1048	Recognition and Management of Cardiac Arrhythmias: Part I. General Principles and Supraventricular Tachyarrhythmias. Journal of Intensive Care Medicine, 1998, 13, 15-31.	1.3	1
1049	Conclusions and Questions from Large Trials of Anticoagulants in Patients with Atrial Fibrillation. Developments in Cardiovascular Medicine, 1998, , 43-48.	0.1	0
1051	Anticoagulant Therapy with Warfarin for Thrombotic Disorders. Handbook of Experimental Pharmacology, 1999, , 353-366.	0.9	0
1052	Moderate Effect of GGCX Polymorphisms on Patients Warfarin Dosage Requirement- A Meta-Analysis. American Journal of Life Sciences, 2015, 3, 7.	0.3	1
1053	Retrospective analysis of patients on warfarin therapy undergoing surgical procedures: An Institution based study. Journal of Advanced Medical and Dental Sciences Research, 2016, 4, 109-114.	0.1	0
1055	Antiplatelet Therapy in Patients with Coronary Artery Disease. , 2017, , 1361-1371.		0
1056	OBSOLETE: Clinical Trials for Atrial Fibrillation - What do we know?. , 2018, , .		0
1057	Anticoagulation Patterns in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention in an Academic Center. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3785-3789.	0.2	0
1058	Pharmacologic Management of Atrial Fibrillation and Flutter. Contemporary Cardiology, 2020, , 359-407.	0.0	0
1060	Prevalence of atrial fibrillation, oral anticoagulation prescription and associated factors in Brazilian older adults. Geriatrics Gerontology and Aging, 2020, 14, 228-235.	0.3	0
1061	Benefit and harm of anticoagulation in the prevention of thromboembolic stroke for nonvalvular atrial fibrillation in haemodialysis patients: a Top End of Northern Australia study. Internal Medicine Journal, 2023, 53, 517-524.	0.5	1
1064	Spezielle therapeutische Probleme im höheren Alter. , 2005, , 98-122.		0
1065	Therapie des Vorhofflimmerns. , 2006, , 115-123.		0

#	ARTICLE	IF	CITATIONS
1066	Monitoring Chronic Oral Anticoagulant Therapy. , 1997, , 495-515.		0
1067	Hemorrhagic Complications. , 1997, , 519-544.		0
1068	Cardiac Valves. , 2006, , 489-522.		0
1069	The cumulative risks of prolapsing mitral valve. 40 years of follow-up. Texas Heart Institute Journal, 1994, 21, 267-71.	0.1	5
1070	Treatment of nonvalvular atrial fibrillation. Western Journal of Medicine, 1995, 162, 331-9.	0.3	7
1071	Nonvalvular atrial fibrillation: evidence for a prothrombotic state. Cmaj, 1997, 157, 673-81.	0.9	18
1072	Atrial fibrillation and stroke: what we know, what's new, and what we should do now. Cmaj, 1997, 157, 695-7.	0.9	0
1073	Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. Cmaj, 1999, 161, 493-7.	0.9	11
1074	Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice. British Journal of General Practice, 1995, 45, 153-8.	0.7	60
1075	Arrhythmias. Journal of the Royal Society of Medicine, 1994, 87, 87-90.	1.1	0
1076	Anticoagulation and atrial fibrillation. Putting the results of clinical trials into practice. Western Journal of Medicine, 1995, 163, 145-52.	0.3	3
1077	Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions. Western Journal of Medicine, 1995, 163, 177-9.	0.3	0
1078	Atrial fibrillation pearls and perils of management. Western Journal of Medicine, 1996, 164, 425-34.	0.3	3
1079	A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences. British Journal of General Practice, 1998, 48, 1775-8.	0.7	21
1080	Comorbidity associated with atrial fibrillation: a general practice-based study. British Journal of General Practice, 2001, 51, 884-6, 889-91.	0.7	25
1081	Reproductive technology and postmenopausal motherhood. Cmaj, 1994, 151, 353, 355.	0.9	1
1082	AIDS comes to the classroom. Cmaj, 1994, 151, 1016-9.	0.9	0
1083	Peacekeeping stress prompts new approaches to mental-health issues in Canadian military. Cmaj, 1994, 151, 1484-9.	0.9	0



#	ARTICLE	IF	CITATIONS
1084	No stone left unturned at Montreal hospital's clinical research unit. Cmaj, 1994, 151, 1742-5.	0.9	0
1085	New prenatal screening procedures raise spectre of more "wrongful-birth" claims. Cmaj, 1995, 152, 734-7.	0.9	3
1086	Canadian atrial fibrillation anticoagulation study: were the patients subsequently treated with warfarin? Canadian Atrial Fibrillation Anticoagulation Study Group. Cmaj, 1996, 154, 1669-74.	0.9	3
1087	Antithrombotic therapy in atrial fibrillation. Canadian Family Physician, 1996, 42, 1341-5.	0.1	3
1088	Anticoagulation in atrial fibrillation. Is there a gap in care for ambulatory patients?. Canadian Family Physician, 2004, 50, 1244-50.	0.1	6
1089	The role of coumadin and aspirin in atrial fibrillation. Transactions of the American Clinical and Climatological Association, 1996, 107, 79-85; discussion 85-6.	0.9	0
1090	Screening, isolation, and decolonization strategies for vancomycin-resistant enterococci or extended spectrum Beta-lactamase-producing organisms: a systematic review of the clinical evidence and health services impact. CADTH Technology Overviews, 2013, 3, e3202.	0.5	13
1091	Stroke Prevention in Atrial Fibrillation. Journal of Atrial Fibrillation, 2010, 3, 279.	0.5	3
1092	Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents. Journal of Atrial Fibrillation, 2013, 6, 825.	0.5	0
1093	Prevention of Stroke by Antithrombotic Therapy in Patients with Atrial Fibrillation. Journal of Atrial Fibrillation, 2013, 5, 732.	0.5	0
1094	Screening for Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2022, 327, 368.	3.8	23
1096	Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. European Heart Journal Supplements, 2022, 24, A19-A31.	0.0	6
1097	Evaluation and Interventional Management of Cardiac Dysrhythmias. Surgical Clinics of North America, 2022, 102, 365-391.	0.5	0
1098	Atrial Fibrillation: Antithrombotic Therapy. , 0, , 548-555.		0
1099	Treatment of Patients with Stroke. , 0, , 839-852.		0
1100	Introduction to Decision Analysis. , 0, , 56-70.		0
1103	Left atrial appendage closure with Watchman device: Insights from the first-ever Tunisian experience and six-year follow-up.. Tunisie Medicale, 2021, 99, 525-530.	0.2	0
1104	Qualidade da AnticoagulaÃ§Ã£o Oral em Pacientes com FibrilaÃ§Ã£o Atrial em um Hospital TerciÃ¡rio no Brasil. Arquivos Brasileiros De Cardiologia, 2022, , .	0.3	2

#	ARTICLE	IF	CITATIONS
1105	Atrial Fibrillation and Stroke. , 0, , .		0
1106	Mechanical versus bioprosthetic valves in chronic dialysis: a systematic review and meta-analysis. Canadian Journal of Surgery, 2022, 65, E450-E459.	0.5	8
1107	Left Atrial Appendage Occlusion: Current Stroke Prevention Strategies and a Shift Toward Data-Driven, Patient-Specific Approaches. , 2022, 1, 100405.		2
1109	The Impact of Landscape Changes on Data and Safety Monitoring Board Oversight of Clinical Trials. , 2022, 1, .		1
1110	Guidelines for the clinical management of atrial fibrillation: a practical perspective. Swiss Medical Weekly, 0, , .	0.8	5
1111	Predictors of warfarin use in patients with non-valvular atrial fibrillation who presented to the cardiology outpatient clinic of a tertiary hospital in Turkey: an observational study. Turkish Journal of Medical Sciences, 0, , .	0.4	7
1114	Terapia antitromb�tica en la fibrilaci�n auricular no valvular, a la luz de la medicina basada en la evidencia. Iatreia, 0, , .	0.1	0
1115	Anticoagulation for Atrial Fibrillation: A Review of Current Literature and Views. Cardiology in Review, 2024, 32, 131-139.	0.6	4
1117	Cardioembolic stroke: An update on etiology, diagnosis and management. Annals of Indian Academy of Neurology, 2008, 11, 52.	0.2	11